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Comparison of Sevoflurane with Propofol for 
Laryngeal Mask Airway Insertion in Adults 
 
 
Abstract 
 
We conducted a prospective, randomized, controlled trial to compare 
the quality and ease of laryngeal mask airway (LMA) insertion after either 
rapid inhaled sevoflurane or IV propofol induction of anesthesia. 
 
Placement of the LMA under inhalational anesthesia is not performed 
universally in adult patients. A famous method of anesthesia for Laryngeal 
Mask airway placement is with use of intravenous propofol, it has the 
benefits of inducing anesthesia quickly and depressing reflexes of upper 
airway. On the other hand, propofol is not ideal agent, it is associated with 
many side effects like apnea, pain on injection and hypotension. Recently, 
single VCB technique induction of inhalational sevoflurane is used as an 
alternate method to intravenous induction of propofol in adult patients. 
Sevoflurane induction method is quick, with greater acceptance, better 
hemodynamic profiles and slight excitatory phenomena. Sevoflurane can be 
used for both maintenance and induction of anesthesia.  It made the 
conversion period easier. Hence, we compared sevoflurane inhaled induction 
and propofol IV induction. 
After getting the Institutional Ethical Committee approval ,eighty 
adult patients of American society of Anesthesiologists Physical status 1 &2 
of either sex undergoing minor surgical procedures are allocated  randomly 
in to 2 groups, Group A (propofol induction) and Group B (sevoflurane 
induction). 
LMA was inserted more rapidly in propofol group than in  patients 
with  sevoflurane group (53.88s vs 80.15s) .There was a  greater incidence 
of  difficulty in mouth opening initially in sevoflurane group. Once mouth 
was possible, the degree of attenuation of laryngeal reflexes was similar. The 
incidence  of complications related to LMA insertion , especially apnoea 
was more frequent in the propofol group. There were two failures  of LMA 
insertion in sevoflurane group. Both groups had stable hemodynamic 
parameters. However , prolonged jaw tightness after the sevoflurane 
inhalational induction  may delay LMA insertion. 
This study shows no significant difference between the two groups 
based on the demographic variables. The time to LMA insertion in 
sevoflurane group was significantly different from propofol.(p value <0.05) 
Successful initial mouth opening in sevoflurane group was significantly 
different from Propofol group.( p value <0.05).The hemodynamic responses 
were significantly different from Sevoflurane ( P value  less than 0.05). 
There was no statistical difference between the two groups in number of 
attempts for Laryngeal Mask Airway insertion. 
 We concluded that, even though extended jaw muscle tightness can 
delay LMA placement in patients with sevoflurane inhalational induction, it 
can be compared favorably with intravenous induction of propofol . 
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INTRODUCTION 
         Laryngeal mask airway was conceived and designed by Archie Brain 
in United Kingdom in 198113. Following prolonged research it was released 
in 1988. It has now got a role in the routine management and has established 
as an airway device in the elective setting where the procedure does not 
warrant tracheal intubation. 
         The Laryngeal mask airway is an airway device used frequently in 
Anesthesia and critical care for airway management1. It is an alternate and 
appropriate airway device to the facemask when endo tracheal intubation is 
not mandatory. Acceptable placement of LMA needs   enough depth of 
anesthesia. 
         This study is undertaken to compare the easiness of insertion of LMA 
using Propofol / Sevoflurane for induction. 
         To match the quality and easiness of LMA placement after 8% 
Sevoflurane induction / Propofol induction4 . 
         ASA physical status 1 or 2 patients were anesthetized with either a 
single vital capacity breath technique with Sevoflurane 8% or IV Propofol 2 
mg/kg, induction produced equally rapid loss of consciousness. 
         Usually for LMA insertion the method of anesthesia is IV propofol 
induction14. Because it has the advantages of rapid induction and depression 
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of reflexes of upper airway.  On the other hand, propofol is not best; it is 
related with severe side effects like reduction in BP, pain during injection, 
and apnoea. 
         In recent times, inhalational induction with sevoflurane using single 
VCB technique has been used3,4. It is an alternate method to intravenous 
induction in adult patients. This method is rapid, with greater acceptancy, 
slight excitatory phenomena and better hemodynamic profiles.  Laryngeal 
Mask Airway placement is more rapid after VCB induction using 8% of 
sevoflurane19,20 This makes the sevoflurane a sole drug for both maintenance 
& induction of anesthesia. It will make conversion period easier. 
         Hence, this study is conducted to compare the consistency, excellence, 
and time to LMA insertion in adults after using sevoflurane induction and 
propofol induction 
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3 
 
AIM OF THE STUDY 
         In our study we compare the easiness of Laryngeal Mask Airway 
insertion using sevoflurane inhalational technique and Propofol intravenous 
induction technique in patients undergoing elective minor surgical procedures.  
The following parameters are compared  
1. Jaw Relaxation 
2. Easiness of insertion 
3. Patient movement 
4. Coughing, Gagging 
5. Laryngospasm 
6. Hemodynamic parameters 
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CLASSIC LMA 
 
 
         The Classic LMA    introduced in the United Kingdom in 1988 and in 
the United States in 1992. It is a substitutive device to the face mask. The 
Classic LMA is used in nearly every hospital and has the wide range of sizes 
from neonates to large adults. The Classic Laryngeal Mask Airway   is 
suitable for elective and day care procedures. It is mostly   used in 
spontaneously breathing patients, but can be used with assisted ventilation 
up to 20 cm H20. 
         Even though it is called the "routine-use" Laryngeal Mask Airway, it is 
also used effectively in emergency situations,   in patients with difficult 
airways, adult and peadiatric resuscitation.   Laryngeal Mask Airway Unique 
is a disposable type of Classic Laryngeal Mask Airway. 
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          The LMA is commonly used in position of a face mask or 
endotracheal tubes during administration of an anesthesia, to provide 
ventilation and passage of endotracheal tube in a patient with difficult 
airway, and to support ventilation during FOB. 
4 types of LMA s are routinely used: 
            Disposable LMA                      Classic LMA              
           
            Proseal LMA   
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Classic Laryngeal Mask Airway 
Disposable Laryngeal Mask Airway 
Proseal Laryngeal Mask Airway 
Fastrach LMA-Intubating LMA 
         An LMA consists of a wide bore tube whose proximal end connects to 
a breathing circuit with a standard 15-mm connector and whose distal end is 
connected to an elliptical cuff that can be inflated through a pilot tube. The 
deflated cuff is lubricated and inserted blindly in to the hypopharynx so once 
inflated the cuff forms a low pressure seal around the entrance to the glottis. 
This requires an anesthetic depth slightly greater than required for the 
insertion of oral airway. 
         A correctly placed cuff is bordered   superiorly by the base of tongue, 
laterally by the pyriform sinuses and inferiorly by the upper esophageal 
sphincter. The LMA partially protects the larynx from pharyngeal secretions 
but not gastric regurgitation and it should remain in place until the patient 
has regained airway reflexes. 
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Advantages;  
Compared with face mask  
• Better seal in bearded patients 
• Hands-free operation 
• Less facial nerve and eye trauma 
• Less cumbersome in ENT operations 
• Less operating room pollution 
• Often easier to maintain airway 
           Compared with endotracheal intubation 
• Useful in difficult airways 
• Compare to endotracheal intubation ,it is minimally invasive  
• Less Laryngospasm & bronchospasm 
• Minimal dental & laryngeal trauma 
• Extensive neck mobility is not necessary 
• Risk of  Endo bronchial and esophageal intubation  is not there 
• Does not require muscle relaxation 
• Airway tube is clear so that any obstruction can be seen 
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For successful insertion of LMA depends on following features: 
 
Choose the appropriate size and check for leaks  
The foremost edge of the deflated cuff must be wrinkle free and facing away 
from the aperture 
Lubricate the back side of the cuff 
Ensure adequate depth of anesthesia before insertion 
Place patient head in sniffing position 
Use index finger to guide the cuff along the hard palate and down in to the 
hypopharynx until an increased resistance is felt. The longitudinal black line 
should always be pointing directly cephalad. 
Inflate with the correct amount of air 
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Obstruction after insertion is usually due to down folded epiglottis or 
transient laryngospasm. 
Avoid pharyngeal suction, cuff deflation or LMA removal until the patient is 
awake. 
LMA Size Patient Weight(Kg) Cuff Volume 
1 Neonates <5kg 4ml 
1 ½ Infant 5-10kg 4 to 7ml 
2 Child 10-20kg Up to 10ml 
2 ½ Child 20-30kg Up to 15ml 
3 Small Adult 30-50kg Up to 30ml 
4 Normal 50-70kg Up to 40ml 
5 Large Adult 70-100kg Up to 40ml 
6 Large Adult >100kg Up to 50ml 
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Propofol 
 
 
Chemical Structure of Propofol 
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         Propofol is a 2,6-diisopropylphenol that is administered intravenously 
as 1 percent solution in an aqueous solution of  ten percent soybean oil, 
2.25percent glycerol, and 1.2 percent  egg phosphatide. This drug is 
chemically distinct from other intravenous hypnotic drugs. Rapid IV 
injection of propofol, 1.5 to 2.5 milligram per kilogram(<15 seconds), yields 
unconsciousness within thirty seconds. Arousing is very quick and complete 
than other IV anesthesia induction drugs. The return of consciousness is 
more rapid, and the most important advantages of propofol are slight 
residual CNS effects.  
           Commercial Preparations 
           Propofol is an insoluble drug that needs a lipid vehicle for 
emulsification. Current formulations of propofol use soybean oil as the oil 
phase and egg lecithin act as the emulsifying agent that is made of long 
chain triglycerides. Diprivan and generic propofol differ with respect to the 
preservatives used and pH of the formulation.  
          Mixing of lidocaine with propofol may result in coalescence of oil 
droplets, which may pose the risk of pulmonary embolism.  
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          A low-lipid emulsion of propofol (Ampofol) contains 5% soybean oil 
and 0.6% egg lecithin but does not require a preservative or microbial 
growth retardant. This formulation is equipotent to Diprivan but is 
associated with a higher incidence of pain on injection.  
Mechanism of Action 
Propofol is reasonably selective modulator of γ- Amino Butyric Acid 
(GABAA) receptors, although it has activity at glycine receptors. Propofol is 
assumed to exert its sedative-hypnotic effects through a Gamma Amino 
Butyric Acid receptor interaction. Gamma Amino Butyric Acid is the 
primary inhibitory neuro transmitter in the brain.  GABA receptor increases 
the transmembrane chloride channel conductance that leads to postsynaptic 
cell membrane hyperpolarization and postsynaptic neuronal function. The 
propofol interaction   with specific components of Gamma Amino Butyric 
Acid A receptors decreases the inhibitory neurotransmitter dissociation, 
GABA from the receptor, thereby increasing the GABA-activated opening 
of the chloride channel duration which results in hyperpolarization of cell 
membranes. 
In contrast to volatile anesthetics, spinal motor neuron excitability, as 
measured by H reflexes, is not altered by propofol, suggesting that 
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immobility during propofol anesthesia is not caused by drug-induced spinal 
cord depression.  
Pharmacokinetics 
Propofol clearance from the plasma exceeds hepatic blood flow, 
emphasize that tissue uptake , as well as hepatic oxidative metabolism by 
cytochrome P450, is vital in drug removal  from the plasma .Liver 
metabolism is quick and wide, results in inactive, metabolites of gucoronic 
acid excreted by the kidneys. Propofol forms 4-hydroxypropofol by   ring 
hydroxylation by cytochrome P450.  The hypnotic activity of 4-
hydroxypropofol is about 1/3 of propofol. Other conjugates are inactive. A 
lesser amount of 0.3% of a dose is excreted unchanged in urine. The 
elimination half-time is 0.5 to 1.5 hours, but the context-sensitive half-time 
for propofol infusions lasting up to eight hours is less than 40 minutes. The 
context-sensitive half-time of propofol is minimally influenced by the length 
of the administration because of metabolic clearance is rapid. However, 
when used as a sedative for prolonged intensive care unit (ICU) care, the 
context-sensitive half-time is highly relevant and should be considered. 
Propofol, has a short effect-site equilibration time, that the special effects on 
the brain occur quickly after intravenous administration. 
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The fact that total clearance of propofol exceeds hepatic blood flow 
consistent with other than hepatic clearance (lung uptake and first-pass 
elimination, kidney excretion) of propofol. Pulmonary uptake of propofol is 
significant and influences the initial availability of propofol.  
Glucoronidation is the major metabolic pathway for propofol and uridine 5′-
diphospho-glucuronosyltransferase isoforms are expressed in the kidneys 
and brain. 
Even though the rapid clearance of propofol by metabolism, in 
patients with cirrhosis of the liver no impaired elimination. Plasma 
concentrations of propofol at the time of awakening are similar in alcoholic 
and normal patients.  Clearance of propofol does not influenced by renal 
dysfunction, despite the observation that nearly three-fourths of propofol 
metabolites are eliminated in urine in the first 24 hours. Plasma clearance of 
propofol decreased in old age patients compared with younger ones. 
Propofol can be administered by continuous infusion because of rapid 
clearance of this drug without an excessive cumulative effect. Propofol 
crosses the placenta readily, and cleared from the neonatal circulation. 
   Clinical Uses 
Propofol can be used as the induction agent of choice for many forms 
of anesthesia, especially in day care procedures. Continuous IV infusion of 
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propofol, a common method for producing IV “conscious” sedation or as 
part of a total IV anesthetic. Administration of propofol as a by infusion of 
continuous technique may be used for patients in the Intensive Care Unit.   
  Induction of Anesthesia 
The induction dose of propofol is 1.5 to 2.5 milligram per kilogram 
intravenous, blood levels of two to six micro grams per milliliter produced 
unconsciousness depending on associated medications and the patient’s age.  
Children require higher induction doses of propofol on a milligram per 
kilogram basis, presumably reflecting a greater volume of central 
distribution and clearance rate is high. Elderly patients have decreased 
clearance rate so they need lower induction dose (25% to 50% decrease) and 
increased pharmacodynamic activity. Awakening typically occurs at plasma 
propofol concentrations of 1.0 to 1.5 µg/mL. The characteristic of propofol 
is complete awakening without residual CNS effects, that makes the 
propofol as the induction agent of choice.  
Intravenous Sedation 
Propofol has short context- sensitive half time, combined with the 
short effect-site equilibration time, makes suitable and titratable drug for IV 
sedation. No remaining sedation and lower occurance of vomiting makes 
propofol well suited for ambulatory conscious sedation techniques. The 
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conscious sedation dose of 25 to 100 microgram per kilogram per min 
intravenous produces minimal pain-relieving and amnesic things. In selected 
patients, midazolam or an opioid may be added to propofol for continuous 
IV sedation. When recovery from conscious sedation, there is sense of 
wellbeing also. Patient-controlled analgesia delivery system set to deliver 
0.7 mg/kg doses of propofol with a 3-minute lockout period has been used as 
an alternative to continuous IV sedation techniques. Propofol has emerged as 
the agent of choice for sedation for brief gastrointestinal endoscopy 
procedures. 
Propofol is administered as a sedative drug during mechanical 
ventilation in the ICU patients and also postoperative patients (cardiac 
surgery, neurosurgery), head injury patients. Propofol gives control of stress 
responses and has anti epileptic and amnesia properties. After cardiac 
surgery, propofol sedation appears to modulate postoperative hemodynamic 
responses by decreasing the incidence and severity of tachycardia and 
hypertension. Increasing metabolic acidosis, lipemic plasma, bradycardia, 
and progressive myocardial failure has been described, particularly in 
children who were sedated with propofol during management of acute 
respiratory failure in the ICU.  
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Maintenance of Anesthesia 
The ideal dose of propofol for maintaining anesthesia is 100 to 300 
microgram per kilogram per minute intravenously mostly combined with a 
shorter -acting opioid. General anesthesia with propofol is usually associated 
with minimal post operative queasiness and vomiting, and awakening is 
quick, with lesser remaining sedative   side effects.  
Antiemetic Effects 
The incidence of postoperative nausea and vomiting is decreased 
when propofol is administered, regardless of the anesthetic technique. 
Propofol (10 to 15 milligram IV)  used in the postanesthesia care for treating 
nausea and vomiting, particularly if it is not of vagal origin.  Propofol is 
generally efficacious in treating postoperative nausea and vomiting at 
plasma concentrations that do not produce significant sedation. Simulations 
indicate that antiemetic plasma concentrations of propofol are achieved by a 
single IV dose of 10 mg followed by 10 µg/kg/minute. Propofol is also used 
to prevent chemotherapy-induced nausea and vomiting. Propofol is more 
effective than ondansetron in preventing postoperative nausea and vomiting. 
Propofol uniformly depresses CNS structures, including subcortical centers. 
Most drugs of known antiemetic efficacy exert this effect via subcortical 
structures, and it is possible that propofol modulates subcortical pathways to 
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inhibit nausea and vomiting or produces a direct depressant effect on the 
vomiting center. 
  Antipruritic Effects 
Propofol, 10 mg intravenously, is efficient in the management of 
pruritus related with regional opioids and cholestasis. The mechanism effect 
may be related to the drug’s ability to depress spinal cord activity. In this 
regard, there is evidence that intrathecal opioids produce pruritus by 
segmental excitation within the spinal cord. 
Anticonvulsant Activity 
Propol has anticonvulsant properties, by presynaptic and postsynaptic 
inhibition of chloride ion channels mediated by GABA. In this view, 
propofol in doses of greater than 1 mg/kg IV decreases seizure duration 35% 
to 45% in patients undergoing electroconvulsive therapy.  
Attenuation of Bronchoconstriction 
Propofol decreases the prevalence of wheezing after induction of 
anesthesia and tracheal intubation in healthy and asthmatic patients 
However, a newer formulation of propofol uses metabisulfite as a 
preservative. Metabisulfite may cause bronchoconstriction in asthmatic 
patients.  Propofol having metabisulfite produces airway resistance in 
patients with history of smoking following tracheal intubation than ethylene 
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diamino tetra acetic acid (EDTA). Therefore, the preservative used for 
propofol can have effects on its ability to attenuate bronchoconstriction. 
Effects on Organ Systems 
CNS 
Propofol reduces (CMRO2), cerebral blood flow, and intracranial 
pressure. Propofol does not raise intracranial pressure in patients with space 
-occupying lesions to produce sedation. However, large dose of propofol 
reduces blood pressure and cerebral perfusion pressure. Cerebrovascular 
autoregulation in response to changes in systemic blood pressure and 
reactivity of the cerebral blood flow to changes in PaCO2 are not affected by 
propofol.  Propofol produces cortical electroencephalographic (EEG) 
changes that are similar to those of thiopental, including the ability of high 
doses to produce burst suppression.  Propofol does not interfere with the 
adequacy of electrocorticographic recordings during awake craniotomy 
performed for the management of refractory epilepsy, provided 
administration is discontinued at least 15 minutes before recordings.  
Cardiovascular System 
Propofol produces decreases in systemic BP, these decreases in BP is 
due to reduced cardiac output and systemic vascular resistance. The 
relaxation of vascular smooth muscle produced by propofol is primarily due 
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to inhibition of sympathetic vasoconstrictor nerve activity. A negative 
inotropic effect of propofol produces negative inotropic activity by reducing 
intracellular calcium availability and inhibition of trans-sarcolemmal 
calcium influx. Stimulation produced by direct laryngoscopy and intubation 
of the trachea reverses the blood pressure effects of propofol. Propofol also 
effectively blunts the hypertensive response to placement of a laryngeal 
mask airway.    
Propofol effects on blood pressure are increased in patients of 
hypotension, old age persons and compromised left ventricular function. To 
prevent this exaggerated effect, adequate hydration must be insisted before 
rapid IV administration of propofol. Even though there is blood pressure 
reduction, no change in pulse rate. However, asystole and bradycardia have 
observed after induction of propofol, results in occasional suggestion that 
anti cholinergic agents be administer while parasympathetic stimulation is 
possible to occur in association with administration of propofol.  
Propofol may reduce sympathetic nervous system activity to a larger 
extent than para sympathetic nervous system activity, results in a majority of 
para sympathetic activity. Propofol drug does not alter sinoatrial or 
atrioventricular node function in normal patients or in patients with Wolff-
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Parkinson-White syndrome, thus making it an acceptable drug to administer 
during ablative procedures.  
Bradycardia-Related Death 
Profound bradycardia and asystole after administration of propofol 
have been described in healthy adult patients, despite prophylactic anti 
cholinergics. The risk has been estimated to be 1.4 in 100,000. Propofol 
anesthesia, compared with other anesthetics, increases the incidence of the 
oculocardiac reflex in pediatric strabismus surgery, despite prior 
administration of anti cholinergics.  
Heart rate responses to IV administration of atropine are attenuated in 
patients receiving propofol compared with awake  patients, this decreased 
responsiveness to atropine cannot be effectively overcome by larger doses of 
atropine suggesting that propofol may induce suppression of sympathetic 
nervous system activity. Treatment of propofol-induced bradycardia may 
require treatment with a direct β agonist such as isoproterenol. 
Lungs 
Propofol produces ventilatory depression, with apnea occurs in 25% 
to 35% patients after anesthesia induction. Opioids enhance ventilatory 
depressive effect of propofol.  A maintenance dose of propofol infusion 
reduces breath rate and tidal volume. The ventilatory response to arterial 
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hypoxemia is also decreased by propofol due to an effect at the central 
chemo receptors. Propofol maintains the effect of Hypoxic Pulmonary 
Vasoconstriction. 
Liver and Kidney Function 
Propofol is not normally affect Liver and kidney function as reflected 
by measurements of liver transaminase enzymes or creatinine 
concentrations. Prolonged infusions of propofol have been associated with 
hepatic cellular injury accompanied by lactic acidosis, brady arrhythmias, 
and rhabdomyolysis as part of the propofol infusion syndrome. Presence of 
phenols causes excretion of green urine, reflecting the presence of phenols 
that indicates long term administration of propofol. 
Intraocular Pressure 
Laparoscopic surgery is associated with increased intraocular pressure 
and some consider laparoscopic surgery with the head down position a risk 
in the presence of preexisting ocular hypertension. In this regard, propofol is 
associated with significant decreases in intraocular pressure that occur 
immediately after induction of anesthesia and are sustained during tracheal 
intubation. Total IV anesthesia with propofol for laparoscopic surgery was 
associated with lower intraocular pressures.  
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Other Side Effects 
Side effects of propofol may reflect the parent drug or actions 
attributed to the oil-in-water emulsion formulation. For example, some of 
the side effects of propofol (bradycardia, pain during injection, risk of 
infection, increased triglyceride levels with prolonged administration, 
potential risk for pulmonary embolism) are due to in huge part to the lipid 
emulsion formulation.  
Allergic Reactions 
The phenyl nucleus and di isopropyl side chain are allergic 
components of propofol. The diisopropyl radical, is present in most of 
dermatologic preparations. Likewise, the phenol nucleus is common to many 
drugs. Indeed, anaphylaxis to propofol during the first exposure to this drug 
has been observed, especially in patients with a history of other drug 
allergies, often to neuromuscular blocking drugs. Propofol-induced 
bronchoconstriction has been described in patients with allergy histories.  
Lactic Acidosis 
Lactic acidosis is known as propofol infusion syndrome has been 
described in adult and pediatric patients receiving long term large-dose 
infusions of propofol (greater than 75 microgram per kilogram per minute) 
for more than 24 hours. Severe, refractory, bradycardia in children in the 
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ICU has been observed with long-term propofol sedation.  Unexpected 
tachycardia occurring during propofol anesthesia should prompt laboratory 
evaluation for possible metabolic acidosis. Measurement of arterial blood 
gases and serum lactate concentrations is recommended.  Metabolic acidosis 
in its early stages is reversible with discontinuation of propofol 
administration.  
The differential diagnosis when propofol-induced lactic acidosis is 
suspected includes hyperchloremic metabolic acidosis associated with large 
volume infusions of 0.9% saline and metabolic acidosis associated with 
excessive generation of organic acids, such as lactate and ketones (diabetic 
acidosis, release of a tourniquet). Measurement of the anion gap and 
individual measurements of anions and organic acids will differentiate 
hyperchloremic metabolic acidosis from lactic acidosis. 
Pro convulsion Activity 
The greater number of propofol-induced “seizures” at the time of 
induction and emergence from anesthesia reveal spontaneous excitatory 
movements of subcortical source. These responses are not thought to be due 
to cortical epileptic activity.  
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Abuse Potential 
Extreme dreaming activity, sentimental behavior, and hallucinations 
have reported in the recovery from low-dose infusions of propofol. 
Addiction to virtually all opioids and hypnotics, including propofol, has 
been described.   
Bacterial Growth 
Propofol robustly supports the expansion of Escherichia coli bacteria 
& Pseudomonas aeruginosa. Clusters of postoperative surgical infections 
manifesting as temperature elevations have been attributed to extrinsic 
contamination of propofol. For this reason, it is recommended that (a) an 
aseptic technique be used in handling propofol as reflected by disinfecting 
the ampule neck surface or vial rubber stopper with 70% isopropyl alcohol; 
(b) the contents of the ampule containing propofol should be withdrawn into 
a sterile syringe immediately after opening and administered promptly; and 
(c) the contents of an opened ampule must be discarded if they are not used 
within 6 hours. In the ICU, the tubing and any unused portion of propofol 
must be discarded after 12 hours.    
Antioxidant Properties 
Propofol has potent antioxidant properties that resemble those of the 
endogenous antioxidant vitamin E. Like vitamin E, propofol contains a 
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phenolic hydroxyl group that scavenges free radicals and inhibits lipid 
peroxidation. A neuroprotective effect of propofol may be at least partially 
related to the antioxidant potential of propofol’s phenol ring structure. For 
example, propofol reacts with lipid peroxyl radicals and thus inhibits lipid 
peroxidation by forming relatively stable propofol phenoxyl radicals.   
Reintroduction of molecular oxygen into formerly ischemic tissues 
(removal of an aortic cross-clamp) can damage partially injured cells. O2 
leads to the production of free O2 radicals, which react with poly 
unsaturated fatty acids of cell membranes resulting in disruption of cell 
membranes. Cardiac cell injury can cause postischemic dysfunction, cardiac 
stunning, and reperfusion cardiac dysrhythmias. Propofol strongly attenuates 
lipid peroxidation in CABG.  
Pain on Injection 
Pain on injection is the most commonly reported adverse event 
associated with propofol administration to awaked patients. This unpleasant 
side effect of propofol occurs in less than 10% of patients when the drug is 
injected into a large vein rather than a dorsum vein on the hand. Preceding 
the propofol with (using the same injection site as for propofol) 1% 
lidocaine or by prior administration of a potent short-acting opioid decreases 
the incidence of discomfort experienced by the patient. The incidence of 
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thrombosis or phlebitis is usually less than 1%. Changing the composition of 
the carrier fat emulsion for propofol to long and medium chain triglycerides 
decreases the incidence of pain on injection.  
Miscellaneous Effects 
Propofol can be administered in patients of hereditary copro 
porphyria. Because it will not trigger malignant hyperthermia. 
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Sevoflurane  
  
                   
                 
                                            
  Chemical structure of Sevoflurane 
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Sevoflurane is a fluorinated methyl isopropyl ether. The sevoflurane 
vapor pressure resembles that of halothane and isoflurane, permitting 
delivery of this anesthetic via a conventional unheated vaporizer. The 
solubility of sevoflurane (blood:gas partition coefficient 0.69)  mimics that 
of desflurane, ensuring punctual  anesthesia induction and recovery after 
anesthesia discontinuation.  Compared with isoflurane, recovery from 
sevoflurane anesthesia is 3 to 4 minutes faster and the difference is 
magnified in longer duration surgical procedures (>3 hours)  Sevoflurane is 
non pungent, has lesser odor, produces bronchodilation parallel in degree to 
isoflurane, and produces the smallest amount degree of airway irritation 
amongst the presently available inhaled anesthetics. For these reasons, 
sevoflurane, like halothane, is acceptable for inhalation induction of 
anesthesia. 
Sevoflurane may be 100-fold more vulnerable to metabolism than 
desflurane, with an estimated 3% to 5% of the dose undergoing 
biodegradation. The resulting metabolites include inorganic fluoride (plasma 
concentrations exceed those that occur after enflurane) and 
hexafluoroisopropanol. The chemical structure of sevoflurane is such that it 
cannot undergo metabolism to an acyl halide. Sevoflurane metabolism does 
not result in the formation of trifluoroacetylated liver proteins and therefore 
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cannot stimulate the formation of antitrifluoroacetylated protein antibodies. 
In this regard, sevoflurane differs from halothane, enflurane, isoflurane, and 
desflurane, all of which are metabolized to reactive acyl halide intermediates 
with the potential to produce hepatotoxicity as well as cross-sensitivity 
between drugs. Sevoflurane is the least likely volatile anesthetic to form 
carbon monoxide on exposure to carbon dioxide absorbents. In contrast to 
other volatile anesthetics, sevoflurane breaks down in the presence of the 
strong bases present in carbon dioxide absorbents to form compounds that 
are toxic in animals The principal degradation product is fluoromethyl-2, 2-
difluoro-1-(trifluoromethyl) vinyl-ether (compound A). Compound A is  
dose dependent renotoxin in rats, causing renal proximal tubular 
injury.Eventhough this finding is a concern, the levels of these compounds 
(principally compound A) that occur during administration of sevoflurane to 
patients are far below speculated toxic levels, even when total gas flows are 
1 L per minute. 
Pharmacokinetics of Volatile agents 
The pharmacokinetics of inhaled anesthetics described by (1) 
Absorption from alveoli into pulmonary capillary blood, (2) Distribution of 
drug   (3) metabolism of drug, (4) Excretion of drug mostly through 
pulmonary system. The pharmacokinetics of volatile anesthetics may be 
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influenced by aging, reflecting decreases in lean body mass and increases in 
body fat. The volume of distribution (Vd) of the central compartment 
(plasma volume) is smaller, whereas the apparent Vd (steady state) for these 
drugs in the elderly is larger, especially for those anesthetics most soluble in 
fat. In addition, impaired pulmonary gas exchange may decrease anesthetic 
clearance with age. Furthermore, reduced cardiac output in the elderly 
decreases tissue perfusion, increases time constants, and may be associated 
with an altered regional distribution of anesthetics. Opposite effects on the 
pharmacokinetics of inhaled anesthetics might be expected in the very 
young. 
A sequence of partial pressure gradients starting from the anesthesia 
machine serve to drive the volatile anesthetic crosswise different levels 
(alveoli, capillaries, cell membranes) to  sites of action in the Central 
Nervous System. The primary purpose of volatile is to attain a steady & best 
possible partial pressure of brain of  the volatile anesthetic drug. 
The CNS and other tissues equilibrate with the partial pressures of 
volatile anesthetics deliver to them by arterial blood (Pa). Likewise, the 
alveolar partial pressures (PA) equilibrate with arterial blood of anesthetics. 
This emphasizes that the PA of inhaled anesthetics mimics the partial 
pressure of brain (PBRAIN) at steady state. This is the reason that PA is 
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used as an index of (1) intensity, (2) recovery from anesthesia, and (3) MAC 
value. This is essential to identify that the same partial pressure exists in 
both phases that means the equilibration. Equilibration is not denoted equal 
opportunity of concentrations in 2 bio phases. 
 Understanding these factors that conclude the Partial pressure of 
alveoli and thus the Partial pressure of brain allows control of the volatile 
anesthetics delivered to brain so as to sustain a steady and optimal anesthesia 
depth. This relationship is applicable because volatile anesthetics are only 
minimally metabolized and as such are excreted from the lung. The 
availability of an “online” readout of end-tidal partial pressure, which at 
equilibrium matches brain partial pressure, makes volatile anesthetic dosing 
easier than intravenous anesthetic dosing. 
Determinants of Partial Pressure of Alveoli 
The partial pressure of alveoli and ultimately the partial pressure of 
brain of inhaled anesthetics are determined by input into the alveoli minus 
uptake   the drug from the alveoli into the arterial blood. Input of anesthetics 
into alveoli depends on the (a) inhaled partial pressure (PI), (b) ventilation of 
alveoli, (c) characteristics of the anesthetia delivery. Uptake of volatile 
anesthetics from the alveoli into the pulmonary capillary blood depends on 
(a) anesthetic solubility in tissues, (b) CO and (c) A-v differences (A-vD). 
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Inhaled Partial pressure 
A high PI delivered from anesthesia machine is required in the initial 
management of anesthetic. A high initial enter offsets the force of uptake, 
accelerating anesthesia induction as reflected by the speed of rise in the PA 
and thus the PBRAIN. By time, as uptake into the blood reduces, the PI 
should reduce to equal the reduced uptake of anesthesia and therefore 
maintain a regular and optimal PBRAIN. If the PI is maintained regular with 
time, the PA and PBRAIN will increase progressively as uptake diminishes. 
Concentration Effect 
The impact of PI on the speed of increase of the PA of an inhaled 
anesthetic is called as the concentration effect. The concentration effect 
states that the higher the PI, the more rapidly the PA approaches the PI. The 
higher PI provides anesthetic molecule input to offset uptake and thus speeds 
the rate at which the PA increases. 
The concentration effect results from (a) a concentrating effect and (b) 
an augmentation of tracheal inflow. The concentrating effect reflects 
absorption of the inhaled anesthetic in a lesser lung volume due to uptake of 
all gases in the lung. At the same time, anesthetic input via tracheal inflow is 
increased to fill the space (void) produced by uptake of gases. 
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Second-Gas Effect 
The second-gas effect reflects the capability of large-volume uptake 
of first gas to speed up the rate of increase of the alveolar partial pressure of 
a concomitantly administered “companion” gas. For instance, the primary 
huge uptake of N2O increases the uptakes of accompanied (second) gases 
such as oxygen and inhaled anesthetics. This augmented uptake of the 2nd 
gas reflects raised tracheal flow of all the volatile gases (1st and 2nd gases) 
and more absorption of  2nd gas or gases in a lesser lung volume 
(concentrating effect) due to  large uptake of  initial gas volume. 
Alveolar Ventilation 
Raised ventilation of alveoli like inspired pressure, promote entry of 
anesthetics to counteract the uptake. Total effect is quick speed of raise in 
the PA toward the PI and thus induction of anesthesia. In addition to the 
increased input, the decreased PaCO2 produced by hyperventilation of the 
lungs decreases cerebral blood flow. Possibly, the impact of augmented 
entry on the speed of rise of PA would be counteracting by reduced 
anesthesia delivery of drug to the Central Nervous System. Decreased 
alveolar ventilation decreases input and thus slows the establishment of a PA 
and PBRAIN necessary for the induction of anesthesia. The larger the 
ventilation of alveoli to functional residual capacity ratio, the more fast is the 
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speed of increase in the alveolar partial pressure. In neonates, this ratio is 
approximately 5:1 compared with only 1.5:1 in adults, reflecting the greater 
metabolic rate in neonates compared with adults. As a result, the rate of 
increase of PA toward the PI and thus the induction of anesthesia is more 
rapid in neonates than in adults 
Impact of Solubility 
The impact of changes in ventilation of alveoli on the speed of raise in 
the alveolar partial pressure toward the PI depends on the anesthetic 
solubility in blood. For example, changes in alveolar ventilation influence 
the speed of increase of the alveolar partial pressure of a soluble anesthetic 
(halothane, isoflurane) more than a poorly soluble anesthetic (nitrous oxide, 
desflurane, sevoflurane). Indeed, the speed of increase in the alveolar partial 
pressure of nitrous oxide is rapid regardless of alveolar ventilation. This 
occurs because uptake of nitrous oxide is limited because of its poor 
solubility in blood. Conversely, uptake of a more blood-soluble anesthetic is 
larger, and increasing alveolar ventilation will accelerate the rate at which 
the PA of the soluble anesthetic approaches the PI. This emphasizes that 
changing from spontaneous breathing to mechanical (controlled) ventilation 
of the lungs, which also is likely to be associated with increased alveolar 
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ventilation, will probably increase the depth of anesthesia (PA) produced by 
a more blood-soluble anesthetic. 
Anesthetic Breathing System  
Breathing system of anesthesia characteristics manipulate the speed of 
raise of PA are  (1)  External breathing system volume, (2)  Volatile 
anesthetic solubility ,  solubility in the plastic and rubber parts of the 
breathing system, and (3) entry of gas from  anesthetic delivery system. 
Anesthetic delivery system volume acts like a barrier to sluggish down the 
achievement of the alveolar partial pressure. Large gas flow (5 to 10 L per 
minute) from the anesthetic delivery system reverse   buffer effect. Volatile 
agent solubility in the components of the breathing system of anesthesia 
primarily reduces speed at which the PA increases. At termination of the 
anesthesia administration, however, reverse of the partial pressure slope in 
breathing system of anesthesia resulted in elution of the anesthetic, which 
slow down the speed at the PA decreases. 
Solubility 
The drug solubility in tissue and blood is reflected by the partition 
coefficient. A partition coefficient is allocation share describes how volatile 
anesthetic allocates itself among 2 phases at the equilibrium (partial 
pressures equal in both phases). For example, a blood: gas partition 
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coefficient of 0.5 denotes that the concentration of volatile anesthetic in  
blood is half that present in the alveolar gases when  partial pressures of the 
anesthetic in these 2 phases is indistinguishable. Similarly, a brain: blood 
partition coefficient of 2 indicates a concentration of anesthetic in the brain 
is twice that in the blood when partial pressures of anesthetic are 
indistinguishable at both sites. 
Partition coefficients may be thought of as reflecting the relative 
capacity of each phase to accept anesthetic. Partition coefficients are 
indirectly proportional to temperature   that is gas solubility in the liquid is 
decreased while temperature of liquid increases. 
Coefficients of Blood –Gas partition 
Speed of raise of the PA toward the PI (maintained constant by 
mechanical ventilation of the lungs) is inversely related to the solubility of 
the drug in blood. Based on their blood: gas partition coefficients, inhaled 
anesthetics are categorized traditionally as soluble, intermediately soluble, 
and poorly soluble. Blood could be measured the pharmacologically inactive 
reservoir, the size is determined by   drug solubility in blood. While blood: 
gas partition coefficient is elevated, a huge quantity of anesthetic should 
dissolved in blood earlier than the arterial pressure equilibrates with alveolar 
partial pressure. For example, the high blood solubility of methoxyflurane 
  
38 
 
slows the rate at which the PA and Pa increase relative to the PI, and the 
induction of anesthesia is slow. The impact of large solubility of blood on 
the speed of augment of Pa can be counterbalance to few degrees by 
escalating the inspired partial pressure above that required for maintenance 
of anesthesia. This is termed the overpressure technique and may be used to 
speed the induction of anesthesia, recognizing that sustained delivery of a 
high PI will result in an anesthetic overdose. 
When blood solubility is small, least amounts of inhaled anesthetic 
must dissolved prior to equilibration is achieved; therefore, the speed of 
raise of PA and Pa, and thus onset-of-drug effects such as the induction of 
anesthesia, are rapid. For example, the inhalation of a constant PI of nitrous 
oxide, desflurane, or sevoflurane for about 10 minutes results in a PA that is 
≥80% of the PI. Use of an overpressure technique with sevoflurane is more 
readily accepted by patients because this anesthetic is less pungent than 
desflurane. Indeed, one or more vital capacity breaths of high concentrations 
of sevoflurane (7% with 66% nitrous oxide) may result in loss of the eyelash 
reflex. 
  Coefficients of Tissue- Blood partition 
The Tissue:blood partition coefficients conclude uptake of anesthetic 
into tissues and the time taken for equilibration of tissues with the partial 
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pressure of arterial blood. This time for equilibration could be estimated by 
calculate the time constant (quantity of volatile agent dissolved in tissue 
divided by tissue blood flow) for every tissue. One time constant on an 
exponential curve represents 63% equilibration. Three time constants are 
equivalent to 95% equilibration. For volatile anesthetics, equilibration 
between the Pa and PBRAIN depends on the anesthetic’s blood solubility 
and requires 5 to 15 minutes (three time constants). Fat has an enormous 
capacity to hold anesthetic, and this characteristic, combined with low blood 
flow to this tissue, prolongs the time required to narrow anesthetic partial 
pressure differences between arterial blood and fat. For example, 
equilibration of fat with isoflurane (three time constants) based on this 
drug’s fat:blood partition coefficient and an assumed fat blood flow of 2 to 3 
mL per minute per 100 g fat is estimated to be 25 to 46 hours. Fasting before 
elective operations results in transport of fat to the liver, this could increase 
anesthetic uptake by this organ and modestly slow the rate of increase in the 
PA of a volatile anesthetics during anesthesia induction. 
  Anesthesia recovery  
Anesthesia recovery is depicted by the rate of decrease in the 
PBRAIN as reflected by the PA the rate of washout of anesthetic from the 
brain should be rapid because inhaled anesthetics are not highly soluble in 
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brain and the brain receives a large fraction of the cardiac output. Although 
similarities exist between the rate of induction and recovery, as reflected by 
changes in the PA of the inhaled anesthetic, there are important differences 
between the two events. In contrast to induction of anesthesia, which may be 
accelerated by the concentration effect, it is not possible to speed the 
decrease in PA by this mechanism.  
Furthermore, at the conclusion of every anesthetic, the concentration 
of the volatile agent in tissues depending highly on solubility of the inhaled 
drug and the duration of its administration. This contrasts with tissue 
concentrations of zero at the initiation of induction of anesthesia. The failure 
of certain tissues to reach equilibrium with the PA of the inhaled anesthetic 
during maintenance of anesthesia means that the rate of decrease of the PA 
during recovery from anesthesia will be more rapid than the speed of 
increase of the alveolar partial pressure at the time of anesthesia induction. . 
Indeed, even after a prolonged anesthetic, skeletal muscles probably, and fat 
almost certainly, will not have equilibrated with the PA of the inhaled 
anesthetic.  
Thus, when the PI of an anesthetic is abruptly decreased to zero at the 
conclusion of an anesthetic, these tissues initially cannot contribute to the 
transfer of drug back to blood for delivery to the liver for metabolism or to 
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the lungs for exhalation. As long as gradients exist between the Pa and 
tissues, the tissues will continue to take up anesthetic. Thus, during recovery 
from anesthesia, the continued passage of anesthetic from blood to tissues, 
such as fat, acts to speed the rate of decrease in the PA of that anesthetic. 
Continued tissue uptake of anesthetic will depend on the solubility of the 
inhaled anesthetic and the duration of anesthesia, with the impact being most 
important with soluble anesthetics. For soluble anesthetics recovery from 
anesthesia is prolonged, which is directly proportional to duration of drug 
delivery, whereas for poorly soluble anesthetics like sevoflurane recovery 
time is less. 
Context-Sensitive Half-Time 
Elimination of volatile anesthetics depends on length of anesthesia 
administration and blood-gas solubility of the volatile anesthetic. As with 
propofol, this is possible to apply computer simulation to conclude context-
sensitive half-time for inhaled agents. In this regard, time needs for fifty 
percent reduce in anesthetic concentration of sevoflurane is < five min. and 
this not rise considerably with escalating length of anesthesia. It would 
seem, it is the indication of the primary phase excretion which is a role of 
alveolar ventilation. 
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Pharmacodynamics --Inhaled Anesthetics 
Minimal Alveolar Concentration 
MAC of an inhaled anesthetic is defined as that concentration at 1 
atmosphere that prevents skeletal muscle movement in response to a 
supramaximal painful stimulus (surgical skin incision) in 50% of patients. 
MAC is an anesthetic 50% effective dose (ED50). Immobility produced by 
inhaled anesthetics as measured by MAC is mediated principally by effects 
of these drugs on the spinal cord and only a minor component of immobility 
results from cerebral effects. 
Central Nervous System Effects 
Cerebral metabolic oxygen requirements are decreased in parallel with 
drug-induced decreases in cerebral activity. Drug-induced increases in 
cerebral blood flow may increase intracranial pressure (ICP) in patients with 
space-occupying lesions. The effects of desflurane and sevoflurane on the 
CNS do not differentiate these inhaled anesthetics from the older inhaled 
drugs. 
Seizure Activity 
Sevoflurane like isoflurane, do not produce evidence of convulsive 
activity on the EEG either at deep levels of anesthesia or in the presence of 
hypocapnia or auditory stimulation. Nevertheless, there are reports of 
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pediatric patients with epilepsy and otherwise healthy adults who developed 
EEG evidence of seizure activity during sevoflurane anesthesia. Sevoflurane 
can suppress convulsive activity induced with lidocaine. 
Circulatory Effects 
Drug-induced circulatory effects manifest as changes in heart rate, 
blood pressure, stroke volume, cardiac output,   systemic vascular resistance, 
right atrial pressure cardiac rhythm, and coronary blood flow. Circulatory 
changes of inhaled anesthetics may be dissimilar in the presence of (a) 
mechanical ventilation of the lungs compared with spontaneous breathing, 
(b) preexisting cardiac disorders, or (c) indirect and directly acting drugs on 
the heart. The  circulatory effects of mechanism are diverse  often reflect the 
special effects of volatile anesthetics on (a)cardiac contractility, (b) 
peripheral vascular resistance, and (c) activity of autonomic nervous system. 
Mean Arterial Pressure. 
Sevoflurane produce dose-dependent decreases in mean arterial 
pressure. Sevoflurane increases heart rate only at concentrations of >1.5 
MAC, whereas isoflurane and desflurane tend to increase heart rate at lower 
concentrations.  
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Cardiac Output and Stroke Volume 
Sevoflurane, produces dose-dependent decreases in cardiac output. 
Sevoflurane did decrease cardiac output at 1 and 1.5 MAC, but at 2 MAC 
cardiac output had recovered to nearly awake values.  
Mechanisms of Circulatory Effects 
There is no known single mechanism that explains the cardiovascular 
depressant effects of volatile anesthetics, just as there is none for the 
neurobehavioral effects. Proposed mechanisms include (a) direct myocardial 
depression, (b) inhibition of CNS sympathetic activity, (c) peripheral 
autonomic ganglion blockade, (d) attenuation of carotid sinus reflex, (e) 
reduced cyclic adenosine monophosphate, (f) reduced catecholamine release 
and (g) reduction of calcium ions influx in the course of slow channels. 
Indeed, negative inotropic, vasodilating, and depressant effects on the 
sinoatrial node produced by volatile anesthetics are similar to the effects 
produced by calcium entry blockers. 
Ventilation Effects 
Inhaled anesthetics produce dose-dependent and drug-specific effects 
on the (a) pattern of breathing, (b) ventilatory response to carbon dioxide, (c) 
ventilatory response to arterial hypoxemia, and (d) airway resistance. The 
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PaO2 predictably declines during administration of inhaled anesthetics in the 
absence of supplemental oxygen.  
Sevoflurane Produce dose-dependent increases in the frequency of 
breathing. Tidal volume is decreased in association with anesthetic-induced 
increases in the frequency of breathing. The net effect of these changes is a 
rapid and shallow pattern of breathing during general anesthesia.  
Ventilatory Response to Carbon Dioxide 
Volatile anesthetics produce dose-dependent depression of ventilation 
characterized by reduced hypercarbic drive to the ventilation and increases 
in the PaCO2  
Mechanism of Depression 
The ventilatory depression associated with sevoflurane may result 
from a combination of central depression of medullary inspiratory neurons 
and depression of diaphragmatic function and contractility.  
Ventilatory Response to Hypoxemia 
Sevoflurane is useful during thoracic surgery as it is a potent 
bronchodilator, its low blood-gas solubility permits rapid adjustment of the 
depth of anesthesia, and effects on hypoxic pulmonary vasoconstriction are 
small. 
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Airway Resistance and Irritability 
Sevoflurane decreases airway resistance as much or more than 
isoflurane. Sevoflurane have been administered without evidence of 
bronchospasm to patients with bronchial asthma. 
Hepatic Effects 
Drug Clearance 
Volatile anesthetics may interfere with clearance of drugs from the 
plasma as a result of decreases in hepatic blood flow or inhibition of drug-
metabolizing enzymes.  
Sevoflurane 
Compound A, a product of sevoflurane interaction with carbon 
dioxide absorbents, is hepatotoxic in animals, but the concentration present 
in the anesthesia breathing circuit is far below the toxic level in animals.  
Renal Effects 
Volatile anesthetics produce similar dose-related decreases in renal 
blood flow, glomerular filtration rate, and urine output.  
Vinyl Halide Nephrotoxicity 
Potassium and sodium hydroxide containing co2 absorbents react with 
sevoflurane and eliminate hydrogen fluoride from its isopropyl moiety to 
form breakdown products. The degradation product produced in greatest 
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amounts is fluoromethyl-2,2-difluro-1-(trifluoromethyl) vinyl ether 
(compound A). During closed-circuit anesthesia with sevoflurane 
administered to patients undergoing operations lasting longer than 5 hours, 
the average concentration of compound A in the anesthesia circuit was <20 
ppm and no evidence of renal dysfunction occurred based on measurements 
of blood urea nitrogen and plasma creatinine concentrations. Higher 
concentrations of compound A occurred in the presence of Baralyme (no 
longer clinically available) probably as a result of higher absorbent 
temperatures compared with soda lime. Similarly, carbon dioxide production 
increases the absorbent temperature and thus the production of compound A. 
Probenecid is a selective inhibitor of organic anion transport and 
pretreatment with this drug prevents compound A–induced renal injury in 
rats and may provide similar protection in humans.  
Malignant Hyperthermia 
All volatile anesthetics including desflurane and sevoflurane could 
cause malignant hyperthermia in genetically vulnerable patients even in 
absence of concomitant administration of succinylcholine.  
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Sevoflurane Vaporizer 
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Review of literature 
 Propofol is an intravenous induction agent which has a rapid onset of 
action with good relaxation properties. It is administered as a 1% 
solution. Administration of 1.5-2.5 mg/kg intravenously produces 
unconsciousness within 30 seconds. The rapid induction and rapid return 
of consciousness with minimal residual effects are the most important 
advantages of propofol. 
 The action of propofol is mediated by enhancing γ-aminobutyric acid 
(GABA)–induced chloride current through binding to the β-subunit of 
GABAA receptor leading to depressant action on the Central Nervous 
System. 
 Propofol reduces systolic blood pressure by depression of the 
baroreceptor reflexes. Propofol produces dose dependent depression of 
ventilation with apnea in 25%-35% of patients. Propofol blunts the 
hypertensive response during insertion of laryngeal mask airway. 
 Propofol has the advantages of anti-emetic, anti-convulsant and amnestic 
properties also. The common adverse effects are apnea, hypotension and 
pain on injection. 
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 Laryngeal mask airway (LMA) insertion is rapid in patients with 
Propofol induction. It has the jaw muscles relaxant effect and it prevents 
the laryngeal reflexes during placement of the Laryngeal mask airway. 
 Sevoflurane is an inhalational anesthetic agent. With a blood gas partition 
co-efficient of 0.69% and minimum alveolar concentration of 2.1,it 
ensures rapid  induction and rapid recovery after discontinuation of 
anesthesia. 
 Sevoflurane causes least degree of airway irritation amongst the other 
volatile anesthetics and has smooth conversion to maintenance phase 
without apnea. It is also considered safe in adult patients because of lack 
of nephrotoxicity and minimal metabolism.  
 Sevoflurane associated with delayed jaw muscle relaxation and may take 
a longer time for insertion of laryngeal mask airway. On the other hand, 
it has better hemodynamic profile and can be used in high risk patients. 
 TiLK, Chow Mark YH et.al conducted a study titled  “Comparison of 
sevoflurane with propofol for laryngeal mask airway insertion in 
adults”The study population consisted of 76 un premedicated American 
society of Anaesthesiologists physical status1/,2 patients who are 
anaesthetized with either sevoflurane 8% by using single vital breath 
capacity or i.v induction of propofol 3mg/.kg. They noted that 
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sevoflurane induces quick loss of consciousness (40.5±13.9s vs. 
37.7±9.9s: p value greater than 0.05) but laryngeal mask airway was 
inserted more quickly in patients with propofol induction (74±29s vs. 
127±35s: p value less than 0.01) and needs lesser attempts than the 
sevoflurane group. Both the groups have stable haemodynamic properties 
& noble patient gratification. They concluded that  the sevoflurane 8% 
VCB induction compares favourably with i.v induction of Laryngeal 
mask airway placement in adults, although sustained jaw tightness may 
delay LMA placement.1 
 Molloy ME, Buggy DJ et.al (1999) : conducted a study titled “Propofol 
or sevoflurane for laryngeal mask airway insertion”.  The study 
population consisted of eighty eight patients of American Society of 
Anesthesiologists I or II underwent general anaesthesia for the elective 
surgeries allocated into 2 groups. Patients in Propofol group (n=44) 
received 2.5mg/kg propofol intravenously and in  Sevoflurane group 
(n=44) received sevoflurane 8% in N2O 50% and O2 50%. LMA 
placement is attempted at 1 min interval from loss of eyelash reflex. The 
mean time to successful laryngeal mask airway placement is 1.3 minutes 
in propofol group, 2.2 minutes in Sevoflurane group. They noted that 
complications were similar in both groups. They concluded that, 
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modified vital capacity breath inhalational induction with sevoflurane 8% 
is efficient for laryngeal mask airway placement in many cases, but it 
takes  longer time than the propofol.2 
 Philip BK, Lambard L et.al (1999): conducted a study titled 
“Comparison of vital capacity induction with sevoflurane to intravenous 
induction with propofol for adult ambulatory anaesthesia”. In this study 
there were fifty six patients allocated randomly to receive either 8% 
sevoflurane in 75% Nitrous Oxide/Oxygen from already primed circuit 
(VC group n=32 patients) or propofol 2mg/kg bolus (IV group n=24) and 
time to induction, loss of consciousness and side effects are monitored. In 
the VC group patients, 59% have lost responsiveness in one breath taking 
39±3s. All Vital capacity patients finished the induction and all measures, 
induction time are appreciably shorter time for Vital capacity group than 
intravenous group. They concluded that Vital capacity induction with 
sevoflurane is an satisfactory alternative to propofol intravenous 
induction of general anaesthesia for the adult ambulatory anaesthesia.3 
 V Priya,  JVDivatia et.al (2002) : conducted a study titled “A 
comparison of propofol vs sevoflurane for laryngeal mask airway 
insertion”. Fifty female patients of American Society of 
Anesthesiologists grade I/II are randomly allocated into 2 groups (n=25 
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in every group)- Group S (inhalational sevoflurane) and group P 
(intravenous propofol). Group P received i.v propofol mean dosage 
2.5mg/kg and group S 8% sevoflurane in 50% Nitrous Oxide and 50% 
Oxygen for 30s. After loss of eyelash reflex laryngeal mask airway 
insertion was excellent in group P (64%) than in group S(32%). 72% of 
patients in group P had complete jaw opening when compared to 44% of 
group S. Hence they concluded that, propofol is better than sevoflurane 
for laryngeal mask airway insertion. 
 Kati I, Demirel CB et.al (2003): conducted a study titled “Comparison 
of propofol and sevoflurane for laryngeal mask airway insertion”. In this 
study hundred patients aged between 20 to 40 years are randomly 
assigned into two groups. Group 1 received propofol (2.5mg.kg -1 i.v) for 
induction and the group 2 received sevoflurane 6% (50% Nitrous 
Oxide+50% Oxygen) by the tidal volume technique of inhalational 
anesthesia. In both the groups, insertion of appropriate sized laryngeal 
mask airway was attempted. Laryngeal mask airway placement time is 
found to  significantly lengthier in the sevoflurane group than in the 
propofol group.5 
 GuiQian S, GuoHua Z et.al (2007): conducted a study titled 
“Comparison of propofol and sevoflurane for laryngeal mask airway 
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insertion in elderly patients”. The study population consisted of ninety 
patients aged 60 years or more. They were induced either with i.v 
propofol or with sevoflurane 8% using the vital capacity breath or tidal 
volume breath technique. Laryngeal mask airway was inserted most 
rapidly with propofol (89 ±28s), less with sevoflurane 8% using the vital 
capacity breath (163±34s) and least with tidal volume breath (205±44s) 
techniques.6  
 In the above studies, time taken for insertion of LMA was taken from 
loss of eye lash reflex. As a result of this, Sevoflurane induction using 
tidal volume technique would not produce sufficient systemic 
concentration in a short duration. So in this study, by adding 30 seconds 
to the loss of eyelash reflex, the ease of insertion of LMA is studied. 
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METHODOLOGY 
Study Design: 
A prospective, randomized, controlled trial. This study conducted in 
Govt. Kilpauk Medical College and hospital Chennai. 
Study setting population: 
After getting approval from the Institutional Ethical Committee and 
informed written consent, eighty adult patients under American Society of 
Anesthesiologists physical status 1 and 2 of either sex undergoing elective 
minor surgical procedures were enrolled for this study.   
Inclusion Criteria: 
1. Elective - minor surgical procedures. 
2. Males and females. 
3. ASA physical status 1 – 2  
4. Age above 18 years and below 50 years.  
5. Patients with valid informed consent. 
Exclusion Criteria: 
1. Patients not satisfying inclusion criteria. 
2. Patients with cardiac disease 
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3. Patients with allergic to inhaled anesthetics and propofol.  
4. Known case of malignant hyperthermia or suspected genetic 
propensity. 
5. Smokers (greater than or equal to twenty cigarettes per day). 
6. Patients who are unconscious or severely ill. 
MATERIALS: 
1. Boyles machine with circle CO2 absorber circuit.  
2. Volatile anaesthetic drug –Sevoflurane with vaporizer. 
3. Propofol. 
4.  Classic Laryngeal Mask Airway size 3 and 4. 
Resuscitation kit should be kept ready- Approximate size Endo 
tracheal tubes, Airways, Suction apparatus.   
Patients in both the groups were IV cannulated with 18 G venflon.  
Monitors connected are NIBP, ECG, and Pulse Oxymetry. Premedicated 
with Inj. Glycopyrrolate 0.2mg i.v., Inj. Fentanyl 2microgram per Kilogram, 
Inj. Ranitidine 50 mg i.v., Inj. Ondensetron 0.1mg /kg. Then preoxygenated 
for 3 minutes with 100% O2. 
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Propofol group:  
Patients in the propofol group were preoxygenated with 100 percent 
oxygen for three minutes and anesthetized using propofol 2 milligram per 
kilogram IV, given over a period of thirty seconds.  30seconds after the 
achievement of induction (i.e., sixty seconds after the start of propofol),  jaw 
relaxation was assessed and, if achievable, Laryngeal Mask Airway 
placement was attempted. If not possible, attempts were repeated every 
thirty seconds upto a max.  4 attempts, every time preceded by  intravenous 
boluses of propofol about 0.5 milligram per kilogram . Once the Laryngeal 
Mask Airway was inserted, all the patients were given sevoflurane four 
percent in 67% N2O in O2 at a rate of three litres/minute of fresh gas flow 
for three minutes. Then the sevoflurane concentration was reduced to two 
percent for volatile agent conservation. NIBP, ECG, SPO2 readings were 
recorded for   five minutes in one minute interval. Any failure of placement, 
defined as failure to insert the LMA after 4 attempts, they were rescued with 
suxamethonium twenty five milligrams intravenously. Unless the patient 
suffered from O2 desaturation, controlled breaths were not given. The 
decision of  not to ventilate the patients manually between Laryngeal Mask 
Airway insertions was proposed to avoid eliminating high PCO2 drive, as it 
could lengthen the time of apnoea. The existence of difficulties correlated to   
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induction and placement of the Laryngeal Mask Airway were noted, like 
excitatory movement or withdrawal from pain, gagging, coughing,  apnoea 
and  laryngospasm . At the end of the surgery, the existence of blood on the 
Laryngeal Mask Airway was noted. 
Sevoflurane group 
A closed circuit with circle absorber for CO2, with a 2-Litre breathing 
bag was used. The closed circuit was primed with eight percent sevoflurane 
in a 2:1 of N2O to O2 for one minute at a rate of six liters per minute of 
fresh gas flow. Then the patients   asked to take a deep breath and then 
expire to residual volume. The face mask with primed closed circuit was 
positioned confidently over the face of the patient. The patients   were taught 
to inspire a vital capacity breath and asked to hold it as long as possible.   
Loss of conscious ness was established by testing the eyelash reflex. 
Duration of vital capacity breath-hold was noted and 90s after the induction, 
the jaw relaxation was assessed. 90s was selected because it signifies the 
time at which all patients   finished their Vital capacity breath. If jaw 
relaxation   was not possible, attempts were repeated each thirty seconds 
upto a max.  4 attempts. An attempt of opening of mouth was considered as 
an attempt at placement of Laryngeal Mask airway. At this time, anesthesia 
sustained with sevoflurane 8% and N2O 67% in O2. Once jaw relaxation 
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was possible, Laryngeal Mask Airway insertion was tried, and the extent of 
diminution of reflexes of larynx were assessed.  
If Laryngeal Mask Airway was inserted easily it classified as full;   
placement was associated with   coughing, gagging, or patient movement, it 
classified as partial; when Laryngeal Mask Airway placement was not 
possible, it classified as poor. Three or four sizes of Laryngeal Mask Airway 
were used according to weight of the patient. 
The following parameters were observed 
During induction: 
• Laryngospasm  
• Cough  
• Involuntary movement 
During Laryngeal mask airway insertion 
• Gagging  
• Coughing 
• Involuntary movement 
• Apnea 
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Quality of Laryngeal Mask Airway Insertion 
• Successful LMA insertion 
• Time to LMA insertion (s)  
•  Number of Attempts (n) 
• Successful initial mouth opening 
• Presence of blood on LMA 
• Hemodynamic parameters  
 
 
 
 
 
 
 
  
  
 
OBSERVATIONS AND 
RESULTS 
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OBSERVATION & RESULTS 
Eighty patients of either sex in ASA 1 &2 status undergoing elective 
minor procedures were studied. The data was analysed with SPSS software 
version 19.1 P values less than 0.05 were considered statistically significant. 
Demographic data, the time taken for LMA insertion and hemodynamic 
variables among the groups were analysed with unpaired student t test . Chi-
square analysis was used for comparing gender and number of attempts for 
insertion. 
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Comparison of age between Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 33.25 1.3 0.640 0.524 
Sevoflurane 32.10 1.2   
  
                        
The mean age in both groups was around 33 years. Both groups were 
equivalent with regard to age and there was no statistically signifigant 
difference between the two groups. 
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Comparison of Gender between Propofol and Sevoflurane group 
Group Gender Chisquare P value 
 Male Female   
Propofol 13 27 0.24 0.626 
Sevoflurane 11 29   
 
 
   
The gender distribution was comparable in both groups without any 
statistically    significant variation in distribution.  
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 Comparison of weight between Propofol and Sevoflurane group 
  
                                   
The mean weight in both the groups was around 56 kgs. Both the 
groups were comparable with regard to weight. There was no statistically 
significant difference between the two groups in terms of weight. 
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Group Mean SE T stat P value 
Propofol 55.53 1.4 -0.786 0.434 
Sevoflurane 56.93 1.1   
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Comparison of BMI between Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 22.54 0.5 -0.982 0.329 
Sevoflurane 23.12 0.4   
 
 
                        
The mean Body Mass Index was around 22. There was no statistically 
significant difference between the two groups in terms of BMI and both the 
groups were comparable with regard to BMI. 
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Comparison of obliteration of eye lash reflex between                             
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 44.40 0.7 -13.977 0.0001 
Sevoflurane 61.45 1.0   
 
                       
The maximum time for obliteration of eyelash reflex was 85secs in 
Sevoflurane group and 60secs in Propofol group. The minimum time for 
obliteration of eyelash reflex was 55secs in Sevoflurane group and 40secs in 
Propofol group.The mean time for obliteration of eyelash reflex was 44secs 
in Propofol group and 61secs in Sevoflurane group. The P value was 
statistically significant. i.e. 0.0001. 
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Comparison of Time to LMA insertion between                                                   
Propofol and Sevoflurane group 
 
 
 
                       
The maximum time for LMA insertion was 32secs in Sevoflurane 
group and 25secs in Propofol group. The minimum time for LMA insertion 
was 18secs in Sevoflurane group and 10secs in Propofol group. 
The mean time for LMA insertion was 19.05secs in Sevoflurane 
group and 12.88secs in Propofol group. The P value was statistically 
significant i.e.0.0001. 
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Propofol 12.88 0.6 -6.993 0.0001 
Sevoflurane 19.05 0.6   
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Comparison of Successful  initial mouth opening between                       
Propofol and Sevoflurane group 
Group Successful initial mouth opening Chisquare P value 
 Yes NO   
Propofol 36 4 4.12 0.03 
Sevoflurane 28 12   
 
                           
The successful initial mouth opening was more in the Propofol group 
compare to Sevoflurane group .The P value was statistically significant i.e. 
0.03.  
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Comparison of Successful LMA Insertion between                                              
Propofol and Sevoflurane group 
Group Successful LMA insertion Chisquare P value 
 Yes NO   
Propofol 36 4 1.57 0.210 
Sevoflurane 32 8   
 
                          
 
The successful LMA insertion was possible in both the groups without 
any statistically significant difference. 
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Comparison of occurrence of Apnoea between                                                        
Propofol and Sevoflurane group 
Group Apnoea Chisquare P value 
 Present Absent   
Propofol 17 23 10.91 0.0009 
Sevoflurane 4 36   
 
                     
The occurance of Apnoea during induction were comparable in both 
groups with statistically important difference. The P value was 0.0009 
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Comparison of occurrence of Gagging between                                            
Propofol and Sevoflurane group 
Group Gagging Chisquare P value 
 Present Absent   
Propofol 6 34 0.11 0.745 
Sevoflurane 5 35   
 
                       
 
Occurrence of Gagging during LMA insertion was comparable in both 
the groups without any statistically significant difference. 
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Comparison of occurrence of Coughing between                                                  
Propofol and Sevoflurane group 
 
 
                
The occurrence of coughing during LMA insertion was comparable in 
both the groups without any statistically significant difference. 
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 Present Absent   
Propofol 7 33 1.83 0.176 
Sevoflurane 3 37   
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Comparison of occurrence of patient movements between Propofol and 
Sevoflurane group 
Group Patient movements Chisquare P value 
 Present Absent   
Propofol 8 32 0.35 0.556 
Sevoflurane 6 34   
 
                  
The occurrence of patient movements during LMA insertion was 
comparable in both the groups without any statistically significant 
difference. 
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Comparison of occurrence of Laryngospasm between                                        
Propofol and Sevoflurane group 
Group Laryngospasm Fisher test P value 
 Present Absent   
Propofol 0 40 1.01 0.50 
Sevoflurane 1 39   
 
                    
The occurrence of Laryngospasm during induction was comparable in 
both the groups without any statistically significant difference. 
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Comparison of number of attempts between Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 1.1 0.04 -1.249 0.215 
Sevoflurane 1.2 0.06   
 
                      
The number of attempts for LMA insertion was comparable in both 
the groups without any statistically significant difference. The only thing 
was time to LMA insertion was prolonged in Sevoflurane group. 
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Comparison of pre induction PR between Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 82.40 0.8 -0.832 0.325 
Sevoflurane 84.03 0.5   
 
Comparison of after induction PR between Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 78.15 0.8 -0.792 0.431 
Sevoflurane 80.70 0.3   
 
Comparison of after LMA PR between Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 83.80 0.8 -1.103 0.119 
Sevoflurane 85.75 0.3   
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Comparison of one minute after LMA PR between                                            
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 86.48 0.9 -0.657 0.527 
Sevoflurane 87.50 0.4   
 
Comparison of three minute after LMA PR between                              
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 84.13 0.8 -0.665 0.508 
Sevoflurane 84.73 0.4   
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Comparison of five minute after LMA PR between                                        
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 83.88 0.8 1.132 0.121 
Sevoflurane 81.20 0.5   
 
                   
Among the groups there were no significant disparity between the 
preinduction, after induction, immediately after insertion of LMA, one, three 
and five minutes post insertion heart rate. 
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Comparison of pre induction mean BP between                                                      
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 92.38 0.8 -1.211 0.230 
Sevoflurane 93.63 0.6   
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Comparison of one minute after LMA mean BP between                                 
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 77.55 0.9 -6.430 0.0001 
Sevoflurane 83.90 0.5   
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Comparison of three minute after LMA mean BP between                    
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 86.78 0.8 -4.653 0.0001 
Sevoflurane 91.35 0.6   
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Comparison of five minute after LMA mean BP between                                  
Propofol and Sevoflurane group 
Group Mean SE T stat P value 
Propofol 93.53 0.8 -0.806 0.423 
Sevoflurane 94.30 0.6   
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 When compared between both groups , there was significant variation 
in the one, three minutes post insertion mean blood pressure. i.e. P value 
0.0001. 
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DISCUSSION 
 
In our study, we observed Sevoflurane single Vital capacity breath 
inhalational induction equates satisfactorily with propofol intravenous 
induction for placement of Laryngeal Mask Airway in adult patients7,10. 
Both sevoflurane and propofol fruitfully induced anesthesia in all patients in 
nearly forty seconds. The hemodynamic parameters were constant for both 
groups. Placement of Laryngeal Mask Airway after Propofol induction was 
achieved in all patients, paralleled with two failures in sevoflurane group. 
Both the induction methods were comparable and statistically insignificant. 
However, the time to successful Laryngeal Mask Airway insertion was 
prolonged in the Sevoflurane group.  
Anesthetic induction and Laryngeal Mask Airway insertion by means 
of sevoflurane have so many benefits, like it allow a better conversion to 
maintenance phase without apnea30,32. The presence of apnoea needs the 
anesthesiologist to ventilate the patient manually. It nullified the benefit of 
anesthesiologist’s free hands afforded by the Laryngeal Mask Airway.    
Sevoflurane prevents pain on injection that was present in propofol 
induction.  There was also less hypotension with sevoflurane. 
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Hall et al7.  Compared Laryngeal Mask Airway insertion by using 8% 
sevoflurane with single breath technique and intravenous propofol 3 
milligram per kilogram. They showed that the adding of N2O in sevoflurane 
group increases speed of induction and safety, but they did not evaluate the 
easiness and excellence of Laryngeal Mask Airway placement at the most 
primitive opportunity. This resulted in slow times for Laryngeal Mask 
Airway insertion (109s and 146s for the propofol group and sevoflurane 
groups, respectively).  
Our major problem about the excellence of Laryngeal Mask Airway 
insertion while using sevoflurane was inadequate mouth opening that 
resulted in two failures in our study. Interestingly, Muzi et al5 reported 
inadequate jaw muscle relaxation after induction of sevoflurane, which 
resulted in failure to insert the Laryngeal Mask Airway in some patients. 
Likewise, Hall et al7 reported long time to jaw muscle relaxation with 
induction of sevoflurane compared with induction of propofol, even though 
they did not suggest any reasons for it. The possible explanation for the 
inadequate mouth opening in our patients was the lag time during which the 
concentration of sevoflurane in alveoli equilibrates with the concentration in 
brain, which leads to incomplete anesthesia during the primary attempt at 
insertion21,27.  Furthermore, jaw muscle relaxation adequate for a jaw thrust 
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might be an indication of sufficient depth of anesthesia. However, Inomata 
and Nishikawa9 dis agree the significance of this lag time. They argue that 
this was unlikely to be significant with sevoflurane induction because of its 
blood-gas partition coefficient is low.  
Propofol is known to have a relaxant effect on jaw muscles, whereas 
inhaled anesthetics may cause accelerated muscle pitch and spasticity. 
Therefore, for a similar depth of anesthesia, there may be greater jaw muscle 
relaxation with propofol16,17.  
In contrast to the inadequate jaw muscle relaxation, there was superb 
lessening of laryngeal reflexes with sevoflurane15. This resulted in a lower 
incidence of distressing Laryngeal Mask Airway insertion in our patients. 
Although Laryngeal Mask Airway insertion is more intimately related with 
deglutition and only require repression of the less sensitive hypopharynx for 
successful insertion13,14. Stimulation of the anterior larynx can occur during 
placement. Therefore, reductions of the reflexes of larynx are necessary to 
lessen the occurrence of pulmonary complications during   placement of 
Laryngeal Mask Airway. However, sevoflurane conserve reflexes of larynx 
at values up to 1.8 Minimum Alveolar Concentration. But in our study 
suggested that sevoflurane could lower reflexes of larynx at the higher 
Minimum Alveolar Concentration values achieved in our patients18,20.  
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The disadvantage of our study was the anesthetic depth between two 
groups were not compared. However, it is not easy to evaluate the depth of 
anesthesia between volatile and intravenous anesthetics. Even though the 
plasma concentration of propofol correlated with depth of anesthesia, the 
correlation between Minimum Alveolar Concentration values and anesthetic 
depth of sevoflurane was not distinct obviously. This is because Minimum 
Alveolar Concentration refers to a state of balance, which was not achieved at 
some point in single Vital Capacity Breath technique induction. Moreover, the 
existence of a lag time between brain and alveolar concentrations can confound 
some attempted association. 
We showed that the safety, excellence,  and consistency of sevoflurane 
single Vital Capacity Breath  induction  makes it, an alternate method to 
intravenous induction of propofol for the placement of the Laryngeal Mask 
Airway in adult patients.  Adjuvant drugs were not necessary in sevoflurane 
group. Sevoflurane Vital capacity breath technique results in equivalent 
complications and stable hemodynamic parameters during the induction and 
placement of Laryngeal Mask Airway. Sevoflurane produces a lesser frequency 
of apnoea and allows better conversion to the phase of maintenance32. On the 
other hand, it may results in a longer time to Laryngeal Mask Airway 
placement   owing to lengthened jaw muscle tightness. 
 
  
 
 
SUMMARY 
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SUMMARY 
Placement of the LMA under inhalational anesthesia is not performed 
universally in adult patients. A famous method of anesthesia for Laryngeal 
Mask airway placement is with use of intravenous propofol, it has the 
benefits of inducing anesthesia quickly and depressing reflexes of upper 
airway. On the other hand, propofol is not ideal agent, it is associated with 
many side effects like apnea, pain on injection and hypotension. Recently, 
single VCB technique induction of inhalational sevoflurane is used as an 
alternate method to intravenous induction of propofol in adult patients. 
Sevoflurane induction method is quick, with greater acceptance, better 
hemodynamic profiles and slight excitatory phenomena. Sevoflurane can be 
used for both maintenance and induction of anesthesia.  It made the 
conversion period easier. Hence, we compared sevoflurane inhaled induction 
and propofol IV induction. 
After getting the Institutional Ethical Committee approval ,eighty 
adult patients of American society of Anesthesiologists Physical status 1 &2 
of either sex undergoing minor surgical procedures are allocated  randomly 
in to 2 groups, Group A (propofol induction) and Group B (sevoflurane 
induction). 
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The following parameters were observed: 
• Jaw muscle relaxation 
• Time to Laryngeal Mask Airway insertion. 
• Number of attempts 
• Patient Movement. 
• Coughing, Gagging. 
• Laryngospasm. 
• Hemodynamic parameters. 
This study shows no significant difference between the two groups 
based on the demographic variables. The time to LMA insertion in 
sevoflurane group was significantly different from propofol.(p value <0.05) 
Successful initial mouth opening in sevoflurane group was significantly 
different from Propofol group.( p value <0.05).The hemodynamic responses 
were significantly different from Sevoflurane ( P value  less than 0.05). 
There was no statistical difference between the two groups in number of 
attempts for Laryngeal Mask Airway insertion.  
 
 
  
 
 
CONCLUSION 
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  CONCLUSION 
In our study we concluded that, inhalational induction by vital 
capacity breath technique using 8%Sevoflurane is an alternate to intravenous 
induction using Propofol for insertion of Laryngeal Mask Airway in adult 
patients.  When compared to intravenous propofol induction, Sevoflurane 
Vital capacity breath technique had stable hemodynamic parameters and 
lesser complications. It allowed smooth conversion to maintenance phase 
and minimal occurrence of apnoea. 
Even though extended jaw muscle tightness can delay LMA 
placement in patients with sevoflurane inhalational induction, it can be 
compared favorably with intravenous induction of propofol . 
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ANNEXURE 

INFORMATION TO PARTICIPANTS 
Investigator:-                Dr.B.S.Thamilselvi 
Name of the Participant:- 
Title: “Comparison of Sevoflurane with Propofol for Laryngeal Mask Airway 
Insertion in Adults”. 
You are invited to take part in this research study. We have got approval from the ICE. You are asked to participate 
because you satisfy the eligibility criteria. 
Voluntary Participation: 
      Your participation in this research is entirely voluntarily. It’s your choice whether to participate or not. 
What is the purpose of this research? 
      Propofol is considered the drug of choice for the insertion of the laryngeal mask airway (LMA) during 
induction of anesthesia because of its depressant effect on airway reflexes. However, propofol has been associated 
with several adverse effects, including hypotension, apnea, pain on injection, and excitatory patient movement. 
Sevoflurane is a nonpungent inhaled anesthetic with a low blood gas solubility coefficient (0.69) and minimal 
respiratory irritant characteristics that make it suitable for inhaled induction of anesthesia and insertion of the LMA. 
Furthermore, sevoflurane, as compared with propofol, has the advantage of providing better hemodynamic stability 
and a smoother transition to the maintenance phase without a period of apnea. 
Benefits: 
        Personally you won’t be benefited in any way directly from the research. But by taking part in the research, you 
will be helping the scientific world to learn more about the drugs and parameters which are used in the study. 
Possible Risks: 
Adverse effects reported are  
- During induction         – apnea, laryngospasm, 
- During LMA insertion – cough, gagging,   
- Postoperatively            – nausea, vomiting, sore throat 
Right to Refuse or Withdraw:  
       You do not have to take part in the research if you do not wish to do so. You may also stop participating in the 
research at any time you choose. It is your choice and all of your rights will be respected. 
 
 
 
You can ask me any more questions about any part of the research study, if 
you wish to. Do you have any questions? 
1. 
2. 
3.     
 
Date:                                                                                                 Signature of the investigator. 
Place: 
 
Signature /Thumb impression                                                     
of the participant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 PATIENT CONSENT FORM 
Study Detail: COMPARISON OF SEVOFLURANCE WITH PROPOFOL FOR 
LARYNGEAL MASK AIRWAY INSERTION IN ADULTS 
Study center: GOVT. KILPAUK MEDICAL COLLEGE HOSPITAL, CHENNAI. 
Patients Name :  
 Patients Age : 
 Identification Number  : 
Patient may check these boxes  
 
I confirm that I have understood  the purpose of procedure for the above study. I have the opportunity to ask 
question and all my questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at anytime without giving 
reason, without my legal rights being affected. 
I Understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical committee and 
the regulatory authorities will not need my permission to look at my health records, both in respect of current study 
and any further research that may be conducted in relation to it, even if I withdraw from the study I agree to this 
access. However, I understand that my identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
I agree to take part in the above study and to comply with the instructions given during the study and faithfully 
cooperate with the study team and to immediately inform the study staff if I suffer from any deterioration in my 
health or well – being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
 
I hereby give permission to undergo complete clinical examination and diagnostic tests including hematological, 
biochemical, radiological tests. 
 
Signature/thumb Impression : 
Patients Name and address : 
 
Signature of investigator  : 
Study investigator’s Name : 
 
 
 
 
 
 

STUDY PROFORMA 
 
GROUP: 
S. NO. :          
NAME:    AGE& SEX   :                         OP/IPNO: 
WT:   HT:     BMI:                            ASA GRADE:                                                      
DIAGNOSIS:     
  
SURGERY PLANNED: 
PREMEDICATIONS: INJ.FENTANYL (2 microgram/Kg) -       micrograms GIVEN AT     
         INJ.ONDANSETRON -4mg 
         INJ.RABEPRAZOLE-20mg 
EVENT TIME(am/pm) 
START OF INDUCTION 
 
OBLITERATION OF EYELASH REFLEX 
 
 
TIME TAKEN FOR INSERTION OF LMA                                               Seconds 
JAW RELAXATION YES/ NO 
LMA INSERTION EASY/ DIFFICULT 
NUMBER OF ATTEMPTS  
 
CONFIRMATION BY 
      1. CHEST EXPANSION 
      2. AUSCULTATION 
      3. CAPNOGRAPHY 
 
COMPLICATIONS  YES               /             NO 
DETAILS OF COMPLICATIONS, IF 
PRESENT 
 
 
 
 
 
  Time PR SBP DBP MBP
 
Baseline value      
Pre induction      
After induction      
Immediately after 
insertion of LMA 
     
1 min after insertion      
3 min after insertion      
5 min after insertion      
 
 
 
 
 
 
 
 
 
 
 
  
 
MASTER CHART 
 
 
 
 
  
 
PROPOFOL GROUP 
 
 
 
 
 SL.No. Name Age IP No Sex Wt Ht BMI ASA Air Way Procedure Size 
1 Parvathy 38 11627 Female 58 168 20.5 ASA-1 MPG-1 
Right 
Fibroadenoma 
excision Size-3 
2 Amutha 40 10344 Female 52 153 22.5 ASA-1 MPG-2 
Fractional 
curettage Size-3 
3 Sekar 42 13113 Male 64 162 24.4 ASA-1 MPG-1 Right URS Size-4 
4 Thangaraj 45 10242 Male 60 155 25 ASA-1 MPG-1 
Right DJ 
stenting Size-4 
5 Anjali 24 10667 Female 32 140 16.4 ASA-1 MPG-1 DHL Size-3 
6 Kuppan 50 11718 Male 57 149 25.7 ASA-2 MPG-1 Left URS Size-4 
7 Yamuna 30 10034 Female 63 160 24.6 ASA-1 MPG-2 TAT Size-3 
8 Sumathy 28 10212 Female 48 151 21.1 ASA-1 MPG-1 DHL Size-3 
9 Senthil 34 11890 Male 61 164 22.7 ASA-2 MPG-1 
Lipoma 
excision-R 
forearm Size-4 
10 Thilaga 25 12490 Female 52 163 19.6 ASA-1 MPG-2 DHL Size-3 
11 Meena 22 10067 Female 53 149 23.9 ASA-1 MPG-1 DHL Size-3 
12 Prema 31 10923 Female 37 150 16.4 ASA-1 MPG-2 TAT Size-3 
13 Govindhan 44 11159 Male 64 161 24.7 ASA-2 MPG-2 R URS Size-4 
14 Mary 42 10990 Female 35 152 16.2 ASA-2 MPG-1 
Fractional 
curettage Size-3 
15 Kokila 23 12667 Female 60 155 25 ASA-1 MPG-1 DHL Size-3 
16 Muniraj 35 12645 Male 57 157 23.1 ASA-2 MPG-1 OIU Size-4 
17 Selvaraj 46 11342 Male 49 163 18.4 ASA-2 MPG-1 Left URS Size-4 
18 Gandhimathy 45 12118 Female 52 160 20.3 ASA-2 MPG-1 
Fractional 
curettage Size-3 
19 Kalpana 26 11783 Female 70 164 26.8 ASA-1 MPG-1 DHL Size-3 
20 Perumal 32 11541 Male 65 153 24.5 ASA-1 MPG-1 L DJ stenting Size-4 
  
SL.No. Name Age IP No Sex Wt Ht BMI ASA Air Way Procedure Size 
21 Kavitha 26 11602 Female 59 168 20.6 ASA-1 MPG-1 DHL Size-3 
22 Vinayak 38 10982 Male 53 153 22.2 ASA-2 MPG-2 R URS Size-4 
23 Jeevitha 23 11267 Female 64 162 24.4 ASA-1 MPG-1 DHL Size-3 
24 Murugaraj 43 11875 Male 60 155 25 ASA-2 MPG-1 OIU Size-4 
25 Seetha 21 10983 Female 53 154 22.3 ASA-2 MPG-1 DHL Size-3 
26 Sumitha 25 10995 Female 57 149 25.7 ASA-1 MPG-2 DHL Size-3 
27 Isakkiyammal 27 11530 Female 63 160 24.2 ASA-1 MPG-1 TAT Size-3 
28 Selvam 40 12498 Male 60 155 25 ASA-2 MPG-2 
Left DJ 
stenting Size-4 
29 Kadhiresan 37 11567 Male 61 164 23.8 ASA-1 MPG-1 OIU Size-4 
30 Meera 27 10359 Female 52 153 22.2 ASA-1 MPG-1 TAT Size-3 
31 Latha 24 11356 Female 54 150 23.8 ASA-1 MPG-1 DHL Size-3 
32 Lakshmi 46 11378 Female 53 154 23.9 ASA-2 MPG-1 
Fractional 
curettage Size-3 
33 Panchali 43 10893 Female 53 152 23.2 ASA-2 MPG-2 
Fractional 
curettage Size-3 
34 Usha 28 11209 Female 36 152 16.3 ASA-1 MPG-2 TAT Size-3 
35 Raja 33 11408 Male 60 164 24 ASA-1 MPG-1 Left URS Size-4 
36 Ramani 30 12305 Female 57 150 23.1 ASA-1 MPG-2 DHL Size-3 
37 Radhika 28 10897 Female 49 163 18.4 ASA-1 MPG-1 TAT Size-3 
38 Rajalakshmi 27 10972 Female 52 160 20.3 ASA-1 MPG-1 TAT Size-3 
39 Sundhari 32 11652 Female 71 163 26.8 ASA-2 MPG-2 DHL Size-3 
40 Sakundhala 30 11387 Female 65 154 24.5 ASA-1 MPG-1 TAT Size-3 
 
  
SL.No. Name 
Start of 
induction 
Obliteration of 
Eyelash 
Reflex(from 
start of 
induction) 
Time to LMA 
Insertion 
Successful intial 
mouth opening LMA Insertion No of Attempts 
1 Parvathy 9.30 am 40secs 12secs Yes Easy 1 
2 Amutha 9.40 am 45secs 10secs Yes Easy 1 
3 Sekar 9.35 am 42secs 10secs Yes Easy 1 
4 Thangaraj 9.45 am 43secs 12secs Yes Easy 1 
5 Anjali 10.00 am 43secs 11secs Yes Easy 1 
6 Kuppan 9.30 am 40secs 13secs Yes Easy 1 
7 Yamuna 9.35 am 45secs 12secs Yes Easy 1 
8 Sumathy 9.45 am 50secs 25secs No Difficult 1 
9 Senthil 9.25 am 42secs 13secs Yes Easy 1 
10 Thilaga 9.35 am 45secs 12secs Yes Easy 1 
11 Meena 9.20 am 42secs 12secs Yes Easy 1 
12 Prema 9.40 am 40secs 10secs Yes Easy 1 
13 Govindhan 9.25 am 42secs 11secs Yes Easy 1 
14 Mary 9.30 am 40secs 13secs Yes Easy 1 
15 Kokila 9.15 am 41secs 14secs Yes Easy 1 
16 Muniraj 9.30 am 45secs 10secs Yes Easy 1 
17 Selvaraj 9.45 am 42secs 14secs Yes Easy 1 
18 Gandhimathy 9.35 am 42secs 11secs Yes Easy 1 
19 Kalpana 9.40 am 48secs 12secs Yes Easy 1 
20 Perumal 9.20 am 52secs 20secs No Difficult 2 
  
SL.No. Name 
Start of 
induction 
Obliteration of 
Eyelash 
Reflex(from 
start of 
induction) 
Time to LMA 
Insertion 
Successful intial 
mouth opening LMA Insertion No of Attempts 
21 Kavitha 9. 30 am 45secs 12secs Yes Easy 1 
22 Vinayak 9.20 am 40secs 10secs Yes Easy 1 
23 Jeevitha 9.45 am 45secs 10secs Yes Easy 1 
24 Murugaraj 9.30 am 42secs 12secs Yes Easy 1 
25 Seetha 9.20 am 40secs 11secs Yes Easy 1 
26 Sumitha 9.35 am 42secs 14secs Yes Easy 1 
27 Isakkiyammal 9.50 am 48secs 12secs Yes Easy 1 
28 Selvam 9.30 am 43secs 10secs Yes Easy 1 
29 Kadhiresan 9.35 am 45secs 12secs Yes Easy 2 
30 Meera 9.20 am 43secs 11secs Yes Easy 1 
31 Latha 9.30 am 48secs 13secs Yes Easy 1 
32 Lakshmi 9.35 am 43secs 14secs Yes Easy 1 
33 Panchali 9.20 am 40secs 10secs Yes Easy 1 
34 Usha 9.25 am 45secs 10secs Yes Easy 1 
35 Raja 9.40 am 48secs 11secs Yes Easy 1 
36 Ramani 9.25 am 42secs 12secs Yes Easy 1 
37 Radhika 9.30 am 44secs 13secs Yes Easy 1 
38 Rajalakshmi 9.45 am 60secs 24secs No Difficult 2 
39 Sundhari 9.25 am 60secs 25secs No Difficult 2 
40 Sakundhala 9.20 am 44secs 12secs Yes Easy 1 
 
  
 
 
SL.No. Name Apnoea Gagging Coughing 
Patient 
Movement Laryngospasm 
Presence of 
Blood on LMA 
1 Parvathy Yes NO NO No No No 
2 Amutha Yes NO NO NO No No 
3 Sekar NO NO NO No NO No 
4 Thangaraj YES NO NO NO NO No 
5 Anjali YES NO NO NO NO NO 
6 Kuppan NO YES YES YES No No 
7 Yamuna YES NO NO YES No No 
8 Sumathy NO NO NO NO No No 
9 Senthil NO NO NO NO No No 
10 Thilaga NO YES YES NO No No 
11 Meena NO NO NO NO No No 
12 Prema YES NO NO NO No NO 
13 Govindhan YES NO NO NO No NO 
14 Mary NO NO NO No No NO 
15 Kokila NO NO NO NO No NO 
16 Muniraj NO YES YES YES No NO 
17 Selvaraj YES NO NO No No NO 
18 Gandhimathy NO NO NO No No No 
19 Kalpana NO NO NO Yes No No 
20 Perumal NO NO NO Yes No Yes 
  
 
 
SL.No. Name Apnoea Gagging Coughing 
Patient 
Movement Laryngospasm 
Presence of 
Blood on LMA 
21 Kavitha NO NO No No No No 
22 Vinayak YES NO YES No No NO 
23 Jeevitha YES NO NO NO No NO 
24 Murugaraj YES NO YES YES No Yes 
25 Seetha YES NO NO NO No No 
26 Sumitha YES NO NO NO NO No 
27 Isakkiyammal YES NO NO No No No 
28 Selvam NO NO NO NO NO No 
29 Kadhiresan NO NO NO NO No No 
30 Meera NO NO NO NO No No 
31 Latha NO NO NO NO No No 
32 Lakshmi YES NO YES NO NO No 
33 Panchali NO NO NO No No No 
34 Usha NO NO NO NO No No 
35 Raja YES NO NO No No No 
36 Ramani YES YES NO NO No No 
37 Radhika NO NO NO No No Yes 
38 Rajalakshmi NO YES YES Yes No Yes 
39 Sundhari NO YES NO Yes No Yes 
40 Sakundhala NO NO NO No No NO 
  
 
SL.No. Name 
Pre 
Induction 
PR 
After 
Induction 
PR 
Immediately 
after 
insertion of 
LMA 
1 min 
after 
insertion 
3 min 
after 
insertion 
5 min 
after 
insertion 
Pre 
induction 
SBP 
Pre 
Induction  
DBP 
Pre 
Induction 
MBP 
1 Parvathy 82 72 78 82 87 84 120 80 93 
2 Amutha 80 71 74 78 84 82 124 86 97 
3 Sekar 86 78 80 85 88 84 130 86 101 
4 Thangaraj 84 75 79 85 87 85 130 78 104 
5 Anjali 78 68 72 76 81 80 120 80 93 
6 Kuppan 80 69 72 75 78 76 124 70 101 
7 Yamuna 86 70 74 78 82 84 110 70 87 
8 Sumathy 84 76 80 85 90 88 110 78 84 
9 Senthil 84 77 80 86 88 83 110 68 87 
10 Thilaga 88 78 82 84 87 86 118 70 95 
11 Meena 78 72 75 78 80 80 124 70 101 
12 Prema 76 67 70 75 78 77 124 80 97 
13 Govindhan 78 69 72 76 79 80 118 78 92 
14 Mary 81 70 75 80 83 82 120 76 95 
15 Kokila 82 68 73 76 79 77 114 68 91 
16 Muniraj 85 74 78 84 88 89 120 86 91 
17 Selvaraj 78 64 70 76 80 82 114 70 91 
18 Gandhimathy 76 68 72 78 81 80 110 72 86 
19 Kalpana 90 72 74 78 80 82 108 70 85 
20 Perumal 78 70 74 81 84 82 110 64 89 
  
 
SL.No. Name 
Pre 
Induction 
PR 
After 
Induction 
PR 
Immediately 
after 
insertion of 
LMA 
1 min 
after 
insertion 
3 min 
after 
insertion 
5 min 
after 
insertion 
Pre 
induction 
SBP 
Pre 
Induction  
DBP 
Pre 
Induction 
MBP 
21 Kavitha 80 76 78 82 84 82 110 70 87 
22 Vinayak 84 78 82 87 90 88 110 72 86 
23 Jeevitha 88 80 84 90 92 91 120 70 94 
24 Murugaraj 86 74 77 81 84 82 114 70 91 
25 Seetha 78 70 73 78 80 84 110 68 87 
26 Sumitha 92 84 86 90 91 94 124 74 92 
27 Isakkiyammal 88 80 83 90 92 93 118 68 97 
28 Selvam 86 80 84 90 90 88 120 74 95 
29 Kadhiresan 90 78 81 87 88 90 110 68 87 
30 Meera 80 72 76 80 84 81 120 72 97 
31 Latha 84 76 78 73 75 78 114 68 91 
32 Lakshmi 78 70 75 81 83 82 110 66 95 
33 Panchali 76 68 73 80 82 80 118 78 92 
34 Usha 92 84 88 95 96 97 120 78 95 
35 Raja 88 80 83 87 89 91 110 70 87 
36 Ramani 82 76 80 85 86 87 108 72 85 
37 Radhika 84 72 76 80 83 85 110 64 89 
38 Rajalakshmi 70 64 67 72 74 76 128 74 104 
39 Sundhari 76 66 70 76 78 80 110 64 89 
40 Sakundhala 80 70 74 79 80 83 120 74 95 
  
 
SL.No. Name 1 min SBP 1 min DBP 1 min MBP 3 min SBP 3 min DBP 3 min MBP 5 min SBP 5 min DBP 5 min MBP 
1 Parvathy 100 68 77 110 72 86 114 76 88 
2 Amutha 98 68 75 104 60 84 110 72 86 
3 Sekar 104 60 84 110 76 85 118 80 91 
4 Thangaraj 104 58 85 106 60 86 114 70 90 
5 Anjali 100 62 79 114 72 90 120 80 93 
6 Kuppan 102 58 83 118 68 95 124 76 98 
7 Yamuna 90 56 71 100 56 81 108 72 84 
8 Sumathy 90 62 69 100 62 79 114 70 90 
9 Senthil 88 58 69 98 54 80 112 68 89 
10 Thilaga 92 64 71 108 60 88 120 70 96 
11 Meena 100 62 79 110 70 87 126 80 99 
12 Prema 104 68 81 110 58 85 120 68 97 
13 Govindhan 92 60 72 114 68 91 124 76 98 
14 Mary 100 64 79 118 70 95 128 80 101 
15 Kokila 90 58 71 100 58 80 112 68 89 
16 Muniraj 102 60 82 114 70 90 120 76 94 
17 Selvaraj 90 54 72 102 60 79 110 70 87 
18 Gandhimathy 88 52 71 100 60 82 110 74 85 
19 Kalpana 88 48 72 102 50 83 114 74 89 
20 Perumal 92 62 71 104 60 84 116 70 92 
 
  
 
SL.No. Name 1 min SBP 1 min DBP 1 min MBP 3 min SBP 3 min DBP 3 min MBP 5 min SBP 5 min DBP 5 min MBP 
21 Kavitha 98 58 79 110 60 90 120 78 94 
22 Vinayak 98 68 75 110 70 87 124 82 97 
23 Jeevitha 104 60 84 118 70 95 126 84 97 
24 Murugaraj 100 62 79 114 60 94 120 76 95 
25 Seetha 90 60 70 102 60 82 110 72 86 
26 Sumitha 92 60 72 102 64 81 114 72 89 
27 Isakkiyammal 96 56 77 110 56 91 122 70 98 
28 Selvam 92 48 76 100 54 82 110 60 90 
29 Kadhiresan 98 54 80 110 60 90 120 76 95 
30 Meera 102 62 81 110 70 87 124 82 97 
31 Latha 106 56 87 120 76 88 126 80 99 
32 Lakshmi 100 52 83 114 70 97 120 74 95 
33 Panchali 88 48 72 100 64 88 112 68 89 
34 Usha 98 52 81 110 56 81 120 70 97 
35 Raja 100 54 82 110 68 87 124 72 100 
36 Ramani 96 54 78 110 70 87 126 80 99 
37 Radhika 100 60 80 114 72 86 128 76 102 
38 Rajalakshmi 102 58 83 110 64 93 122 70 98 
39 Sundhari 104 52 87 116 70 87 120 80 93 
40 Sakundhala 102 58 83 108 60 88 118 70 95 
 
  
 
SEVOFLURANE 
GROUP 
 
 
 
SL.No. Name Age IP No Sex Wt Ht BMI ASA Air Way Procedure Size 
1 Ambika 28 11089 Female 58 168 20.5 ASA-1 MPG-1 TAT Sze-3 
2 Savitha 27 10456 Female 52 153 22.5 ASA-1 MPG-1 TAT Size-3 
3 Dharani 32 11076 Female 64 162 24.4 ASA-2 MPG1 DHL Size-3 
4 Muthu 43 11234 Male 60 155 25 ASA-1 MPG-2 Left URS Size-4 
5 Rani 44 11325 Female 32 140 16.4 ASA-1 MPG-2 
Fractional 
curettage Size-3 
6 Kavitha 25 11347 Female 57 149 25.7 ASA-1 MPG-1 DHL Size-3 
7 Saminathan 46 11098 Male 63 160 24.6 ASA-2 MPG-1 URS right Size-4 
8 Sumitha 25 11078 Female 48 151 21.1 ASA-1 MPG-1 TAT Size-3 
9 Geetha 27 11267 Female 61 164 22.7 ASA-1 MPG-1 TAT Size-3 
10 Anjalai 29 11095 Female 52 163 19.6 ASA-1 MPG-1 DHL Size-3 
11 Rukmani 33 10987 Female 53 149 23.9 ASA-1 MPG-2 DHL Size-3 
12 Gangadevi 28 10867 Female 57 150 25.4 ASA-2 MPG-2 TAT Size-3 
13 Gowri 27 10367 Female 64 161 24.7 ASA-1 MPG-1 DHL Size-3 
14 Ranjitha 35 10874 Female 55 152 23.5 ASA-2 MPG-1 
Fractional 
curettage Size-3 
15 Kadhirvel 48 11238 Male 60 155 25 ASA-2 MPG-1 OIU Size-4 
16 Seetha 26 10675 Female 57 157 23.1 ASA-1 MPG-1 DHL Size-3 
17 Ravi 27 11478 Male 49 163 18.4 ASA-1 MPG-1 Left URS Size-4 
18 Singam 22 11634 Male 52 160 20.3 ASA-1 MPG-1 OIU Size-4 
19 Ponmani 37 10583 Female 70 164 26.8 ASA-1 MPG-2 
Fibroadenoma 
right Size-3 
20 Kaja 38 11487 Male 65 153 24.5 ASA-2 MPG-2 OIU Size-4 
 
 
 
  
SL.No. Name Age IP No Sex Wt Ht BMI ASA Air Way Procedure Size 
21 Kala 42 110753 Female 59 168 20.6 ASA-1 MPG-1 
FIbroadenoma 
left Size-3 
22 Neela 25 10983 Female 53 153 22.2 ASA-2 MPG-2 DHL Size-3 
23 Savithiri 28 10872 Female 64 162 24.4 ASA-1 MPG-1 DHL Size-3 
24 Meera 27 11289 Female 60 155 25 ASA-1 MPG-2 TAT Size-3 
25 Sarala 27 11067 Female 53 154 22.3 ASA-2 MPG-2 TAT Size-3 
26 Janaki 29 11047 Female 57 149 25.7 ASA-2 MPG-1 TAT Size-3 
27 Thenmozhi 29 11285 Female 63 160 24.2 ASA-1 MPG-1 Right URS Size-3 
28 Gomathy 26 11679 Female 60 155 25 ASA-1 MPG-2 TAT Size-3 
29 Balraj 45 10876 Male 61 164 23.8 ASA-1 MPG-2 Left URS Size-4 
30 Samamoorthy 48 11213 Male 52 153 22.2 ASA-1 MPG-1 OIU Size-4 
31 Sivakami 26 10739 Female 54 150 23.8 ASA-2 MPG-1 
Fibroadenoma 
Left Size-3 
32 Banumathy 28 11984 Female 53 154 23.9 ASA-1 MPG-2 TAT Size-3 
33 Pavithra 26 12345 Female 53 152 23.2 ASA-1 MPG-1 DHL Size-3 
34 Pitchai 43 12678 Male 52 153 23.3 ASA-2 MPG-2 Hydrocele right Size-4 
35 Kaliyan 47 12986 Male 60 164 24 ASA-2 MPG-2 Right URS Size-4 
36 Kannamal 28 13214 Female 57 150 23.1 ASA-1 MPG-1 TAT Size-3 
37 Meenatchi 28 12763 Female 49 163 18.4 ASA-1 MPG-1 TAT Size-3 
38 Prema 33 12786 Female 52 160 20.3 ASA-2 MPG-1 
Fibroadenoma 
Right Size-3 
39 Kalaiselvi 24 10437 Female 71 163 26.8 ASA-1 MPG-2 DHL Size-4 
40 Sundaram 28 13467 Male 65 154 24.5 ASA-1 MPG-2 Left URS Size-4 
 
 SL.No. Name 
Start of 
induction 
Obliteration of 
Eyelash 
Reflex(From start 
of induction) Time to LMA Insertion 
Successful intial 
mouth opening LMA Insertion No of Attempts 
1 Ambika 9.35 am 60secs 23secs NO Difficult 2 
2 Savitha 9.45 am 55secs 18secs YES Easy 1 
3 Dharani 9.20 am 62secs 16secs YES Easy 1 
4 Muthu 9.35 am 55secs 17secs YES Easy 1 
5 Rani 9.40 am 60secs 18secs YES Easy 1 
6 Kavitha 9.25 am 62secs 17secs YES Easy 1 
7 Saminathan 9.30 am 58secs 16secs YES Easy 1 
8 Sumitha 9.20 am 62secs 18secs YES Easy 1 
9 Geetha 9.25 am 58secs 18secs YES Easy 1 
10 Anjalai 9.30 am 58secs 25secs NO Difficult 2 
11 Rukmani 9.45 am 60secs 18secs YES Easy 1 
12 Gangadevi 9.20 am 64secs 16secs YES Easy 1 
13 Gowri 9.25 am 60secs 18secs YES Easy 1 
14 Ranjitha 9.40 am 57secs 15secs YES Easy 1 
15 Kadhirvel 9.45 am 58secs 18secs YES Easy 1 
16 Seetha 9.20 am 60secs 16secs YES Easy 1 
17 Ravi 9.25 am 60secs 18secs YES Easy 1 
18 Singam 10.00 am 62secs 27Secs NO Difficult 2 
19 Ponmani 10.15 am 75secs 22secs NO Difficult 2 
20 Kaja 10.10 am 85secs 25secs NO Difficult 2 
 
 
SL.No. Name 
Start of 
induction 
Obliteration of 
Eyelash 
Reflex(Fr0m start 
of induction) Time to LMA Insertion 
Successful intial 
mouth opening LMA Insertion No of Attempts 
21 Kala 9.30 am 58secs 18secs YES Easy 1 
22 Neela 9.45 am 60secs 18secs YES Easy 1 
23 Savithiri 9.30 am 62secs 15secs YES Easy 1 
24 Meera 9.15 am 55secs 17secs YES Easy 1 
25 Sarala 9.40 am 58secs 16secs YES Easy 1 
26 Janaki 9.45 am 56secs 16secs YES Easy 1 
27 Thenmozhi 10.00 am 60secs 19secs YES Easy 1 
28 Gomathy 9.25 am 75secs 26secs NO Difficult 2 
29 Balraj 9.30 am 60secs 19secs YES Easy 1 
30 Samamoorthy 9.20 am 57secs 18secs YES Easy 1 
31 Sivakami 9.30 am 62secs 18secs YES Easy 1 
32 Banumathy 9.35 am 60secs 18secs YES Easy 1 
33 Pavithra 9.40 am 58secs 17secs YES Easy 1 
34 Pitchai 9.35 am 62secs 16secs YES Easy 1 
35 Kaliyan 9.25 am 74secs 30secs NO Difficult 2 
36 Kannamal 9.15 am 57secs 16secs YES Easy 1 
37 Meenatchi 9.30 am 60secs 19secs YES Easy 1 
38 Prema 9.40 am 61secs 18secs YES Easy 1 
39 Kalaiselvi 9.45 am 62secs 17secs YES Easy 1 
40 Sundaram 9.40am 70secs 32secs NO Difficult 2 
 
 
 
  
 
SL.No. Name Apnoea Gagging Coughing 
Patient 
Movement Laryngospasm 
Presence of Blood 
on LMA 
1 Ambika No NO NO NO NO NO 
2 Savitha No NO NO NO NO NO 
3 Dharani NO NO NO NO NO NO 
4 Muthu NO NO NO YES NO NO 
5 Rani NO NO NO NO NO NO 
6 Kavitha NO NO NO NO NO NO 
7 Saminathan NO NO NO NO NO NO 
8 Sumitha NO NO NO NO NO NO 
9 Geetha NO NO YES NO NO NO 
10 Anjalai NO NO NO NO NO NO 
11 Rukmani NO NO NO NO NO NO 
12 Gangadevi NO NO NO NO NO NO 
13 Gowri NO NO NO YES NO NO 
14 Ranjitha YES YES NO YES NO YES 
15 Kadhirvel YES NO NO NO NO NO 
16 Seetha NO NO YES NO NO NO 
17 Ravi NO NO NO NO NO NO 
18 Singam NO NO NO NO NO NO 
19 Ponmani NO NO NO NO NO NO 
20 Kaja NO YES NO NO NO NO 
 
  
SL.No. Name Apnoea Gagging Coughing 
Patient 
Movement Laryngospasm 
Presence of Blood 
on LMA 
21 Kala NO NO NO NO NO NO 
22 Neela NO NO NO NO NO NO 
23 Savithri NO NO YES YES NO YES 
24 Meera NO NO NO NO NO NO 
25 Sarala NO NO NO NO NO NO 
26 Janaki NO NO NO NO NO NO 
27 Thenmozhi NO YES NO NO NO NO 
28 Gomathy NO NO NO NO NO NO 
29 Balraj NO NO NO NO NO NO 
30 Samamoorthy NO NO NO YES YES YES 
31 Sivakami YES YES NO NO NO NO 
32 Banumathy NO YES NO NO NO NO 
33 Pavithra NO NO NO YES NO NO 
34 Pitchai NO NO NO NO NO NO 
35 Kaliyan NO NO NO NO NO NO 
36 Kannamal NO NO NO NO NO NO 
37 Meenatchi YES NO NO NO NO NO 
38 Prema NO NO NO NO NO NO 
39 Kalaiselvi NO NO NO NO NO NO 
40 Sundaram NO NO NO NO NO NO 
 
 
  
SL.No. Name 
Pre 
Induction PR 
After 
Induction 
PR 
Immediately 
after insertion 
of LMA 
1 min after 
insertion 
3 min after 
insertion 
5 min after 
insertion 
Pre 
induction 
SBP 
Pre 
Induction  
DBP 
Pre 
Induction 
MBP 
1 Ambika 88 90 91 86 88 84 124 80 97 
2 Savitha 94 87 92 88 89 85 120 82 93 
3 Dharani 94 90 91 90 87 83 120 86 91 
4 Muthu 92 90 92 87 85 80 126 86 97 
5 Rani 94 90 92 88 84 81 118 80 91 
6 Kavitha 88 87 90 87 84 78 110 78 84 
7 Saminathan 92 89 92 89 86 80 114 78 88 
8 Sumitha 96 93 90 92 88 81 118 80 91 
9 Geetha 92 90 91 88 87 80 116 76 90 
10 Anjalai 92 93 94 87 86 78 122 80 95 
11 Rukmani 84 93 95 90 85 80 120 80 93 
12 Gangadevi 88 91 92 87 83 76 126 82 98 
13 Gowri 90 93 90 88 84 78 124 84 96 
14 Ranjitha 88 90 92 89 82 77 120 86 91 
15 Kadhirvel 89 91 93 88 83 78 116 70 92 
16 Seetha 87 92 90 86 82 75 118 80 91 
17 Ravi 92 92 90 89 86 76 120 80 93 
18 Singam 90 91 93 87 84 75 122 82 94 
19 Ponmani 91 94 92 89 88 80 126 84 98 
20 Kaja 96 92 93 94 90 84 128 84 100 
 
 
 SL.No. Name 
Pre 
Induction PR 
After 
Induction 
PR 
Immediately 
after insertion 
of LMA 
1 min after 
insertion 
3 min after 
insertion 
5 min after 
insertion 
Pre 
induction 
SBP 
Pre 
Induction  
DBP 
Pre 
Induction 
MBP 
21 Kala 93 94 92 89 87 81 120 80 93 
22 Neela 92 93 93 87 88 84 118 82 93 
23 Savithri 90 91 94 86 85 82 116 74 91 
24 Meera 88 89 92 85 84 80 124 80 97 
25 Sarala 90 90 90 86 86 84 120 84 92 
26 Janaki 88 92 93 85 79 80 130 84 102 
27 Thenmozhi 87 92 95 86 80 80 128 78 102 
28 Gomathy 89 91 90 88 82 76 118 70 94 
29 Balraj 91 90 93 89 87 78 120 76 94 
30 Samamoorthy 93 90 93 89 86 78 124 80 97 
31 Sivakami 87 88 92 85 82 76 120 78 94 
32 Banumathy 88 89 90 86 84 75 118 70 94 
33 Pavithra 86 90 88 85 80 76 120 76 94 
34 Pitchai 88 92 87 86 83 79 122 70 98 
35 Kaliyan 94 91 91 88 87 80 120 80 93 
36 Kannamal 90 90 92 87 88 82 124 84 96 
37 Meenatchi 86 88 94 86 82 79 118 80 91 
38 Prema 88 91 95 87 83 74 116 76 90 
39 Kalaselvi 87 89 92 85 82 77 110 70 87 
40 Sundaram 89 90 89 86 83 78 114 72 90 
 
 
 
SL.No. Name 1 min SBP 1 min DBP 1 min MBP 3 min SBP 3 min DBP 3 min MBP 5 min SBP 5 min DBP 5 min MBP 
1 Ambika 110 70 87 108 60 88 114 70 90 
2 Savitha 112 74 87 110 68 87 120 76 94 
3 Dharani 110 80 83 110 72 86 120 72 96 
4 Muthu 106 76 80 112 70 87 120 76 94 
5 Rani 110 70 87 114 74 89 120 78 94 
6 Kavitha 110 72 86 114 72 90 122 70 98 
7 Saminathan 108 70 86 110 70 87 120 76 94 
8 Sumitha 104 70 80 110 68 88 118 68 95 
9 Geetha 106 72 82 114 64 92 120 72 96 
10 Anjalai 104 70 80 110 68 88 122 70 96 
11 Rukmani 110 70 87 108 64 86 120 74 95 
12 Gangadevi 100 68 77 106 70 82 110 68 88 
13 Gowri 106 72 82 112 70 86 118 64 96 
14 Ranjitha 108 76 82 110 66 88 120 72 96 
15 Kadhirvel 110 70 87 114 72 90 120 72 96 
16 Seetha 106 70 83 114 70 91 122 74 97 
17 Ravi 106 72 82 118 70 95 124 68 101 
18 Singam 104 78 78 112 68 89 120 78 94 
19 Ponmani 110 76 84 118 70 95 120 76 94 
20 Kaja 106 76 80 120 72 96 114 70 90 
 
 
 
 
SL.No. Name 1 min SBP 1 min DBP 1 min MBP 3 min SBP 3 min DBP 3 min MBP 5 min SBP 5 min DBP 5 min MBP 
21 Kala 110 74 85 116 64 94 120 72 96 
22 Neela 110 76 84 118 68 95 120 74 95 
23 Savithri 108 68 87 116 68 93 124 70 100 
24 Meera 110 74 85 120 72 96 124 74 99 
25 Sarala 110 74 85 118 74 93 126 70 102 
26 Janaki 106 72 82 120 76 94 124 78 98 
27 Thenmozhi 110 72 86 122 80 95 120 76 94 
28 Gomathy 108 64 86 120 78 94 118 74 93 
29 Balraj 110 72 86 118 78 92 122 70 98 
30 Samamoorthy 110 68 88 120 76 94 124 76 98 
31 Sivakami 108 68 85 110 72 86 118 80 91 
32 Banumathy 110 60 90 118 72 94 114 76 88 
33 Pavithra 110 64 88 116 70 92 110 68 87 
34 Pitchai 108 64 86 120 78 94 116 68 93 
35 Kaliyan 104 68 81 122 70 98 114 70 90 
36 Kannamal 110 68 87 124 76 98 118 76 92 
37 Meenatchi 108 70 84 124 74 98 120 74 95 
38 Prema 104 60 84 120 76 94 116 72 92 
39 Kalaiselvi 100 62 79 110 60 90 114 70 90 
40 Sundaram 100 64 78 112 64 90 110 68 87 
 
 
